MeSH term
Frequency | Condition_Probility | Female | 288 | 0.0 |
Humans | 1128 | 0.0 |
Meta-Analysis | 2 | 1.0 |
Pregnancy | 7 | 0.0 |
Acute Disease | 23 | 0.0 |
Adult | 241 | 0.0 |
Bone Marrow Transplantation/*statistics & numerical data | 2 | 2.0 |
Comparative Study | 148 | 0.0 |
Cord Blood Stem Cell Transplantation/*statistics & numerical data | 2 | 2.0 |
Fetal Blood/transplantation | 2 | 2.0 |
Leukemia/*therapy | 2 | 1.0 |
Patient Selection | 2 | 1.0 |
Aged | 106 | 0.0 |
Cardiac Output, Low/*mortality | 3 | 5.0 |
Coronary Arteriosclerosis/mortality | 3 | 5.0 |
Risk | 4 | 0.0 |
Surgical Procedures, Elective/*mortality | 3 | 5.0 |
Time Factors | 48 | 0.0 |
Animals | 266 | 0.0 |
DNA Damage | 2 | 0.0 |
Drug Delivery Systems | 2 | 2.0 |
Gene Expression | 23 | 0.0 |
*Education, Medical, Graduate | 2 | 6.0 |
*Educational Status | 2 | 6.0 |
*Students, Medical | 2 | 5.0 |
Surgery/*education | 2 | 5.0 |
African Continental Ancestry Group | 2 | 0.0 |
United States | 5 | 0.0 |
*CpG Islands | 3 | 3.0 |
Dendritic Cells/*immunology | 61 | 25.0 |
Flow Cytometry | 217 | 3.0 |
Lymphocyte Activation | 147 | 4.0 |
Lymphocyte Culture Test, Mixed | 116 | 18.0 |
Macrophages/*immunology | 8 | 3.0 |
Mice | 155 | 0.0 |
Mice, Inbred C57BL | 43 | 1.0 |
Research Support, Non-U.S. Gov't | 757 | 0.0 |
Antigens, CD/*biosynthesis | 27 | 14.0 |
Antigens, CD28/biosynthesis | 5 | 16.0 |
Antigens, CD80/biosynthesis | 33 | 61.0 |
Antigens, Differentiation/biosynthesis | 6 | 11.0 |
Gene Expression Regulation | 17 | 0.0 |
Jurkat Cells | 13 | 0.0 |
Lipopolysaccharides/*immunology | 2 | 2.0 |
Macrophages/*drug effects/immunology | 2 | 22.0 |
Membrane Glycoproteins/biosynthesis | 50 | 32.0 |
T-Lymphocytes/*drug effects/immunology | 6 | 6.0 |
Adolescent | 60 | 0.0 |
English Abstract | 24 | 0.0 |
Middle Aged | 168 | 0.0 |
Retrospective Studies | 5 | 0.0 |
Transcription, Genetic/immunology | 3 | 3.0 |
Antigens, CD/*blood | 10 | 5.0 |
B-Lymphocytes/immunology | 15 | 2.0 |
Enzyme-Linked Immunosorbent Assay | 25 | 0.0 |
Male | 233 | 0.0 |
Membrane Glycoproteins/*blood | 9 | 16.0 |
T-Lymphocytes/immunology | 93 | 6.0 |
Antigen-Presenting Cells/*immunology | 24 | 16.0 |
B-Lymphocytes/*immunology | 31 | 3.0 |
Cells, Cultured | 317 | 1.0 |
Immunoglobulins/biosynthesis | 20 | 19.0 |
Immunologic Memory | 10 | 3.0 |
Interferon Type II/biosynthesis | 20 | 4.0 |
Interleukin-5/biosynthesis | 3 | 8.0 |
T-Lymphocytes/metabolism | 10 | 3.0 |
Up-Regulation | 57 | 2.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 44 | 0.0 |
Antigen-Presenting Cells/physiology | 4 | 7.0 |
Antigens, CD/analysis | 60 | 3.0 |
Antigens, CD40/analysis | 13 | 52.0 |
*Drosophila Proteins | 10 | 0.0 |
Histocompatibility Antigens Class II/analysis | 14 | 7.0 |
Membrane Glycoproteins/analysis | 46 | 17.0 |
Monocytes/*immunology | 23 | 5.0 |
Pregnancy Trimester, Third | 2 | 1.0 |
Receptors, Cell Surface/analysis | 3 | 3.0 |
Research Support, U.S. Gov't, P.H.S. | 193 | 0.0 |
Antigen Presentation/immunology | 21 | 27.0 |
Antigens, CD/metabolism | 81 | 9.0 |
Antigens, CD56/analysis | 2 | 3.0 |
Antigens, CD80/metabolism | 46 | 56.0 |
Cell Culture Techniques | 24 | 5.0 |
Cytokines/immunology | 6 | 4.0 |
Dendritic Cells/immunology | 8 | 5.0 |
Genes, MHC Class II/immunology | 3 | 20.0 |
HLA-DR Antigens/*metabolism | 3 | 5.0 |
Killer Cells, Natural/*immunology | 8 | 1.0 |
Lymphocyte Activation/immunology | 47 | 8.0 |
Membrane Glycoproteins/metabolism | 66 | 11.0 |
T-Lymphocyte Subsets/*immunology | 5 | 0.0 |
Antigens, Bacterial/immunology | 6 | 5.0 |
Antigens, T-Independent/immunology | 2 | 22.0 |
CD4-Positive T-Lymphocytes/immunology | 29 | 3.0 |
Gene Expression Regulation/*immunology | 2 | 1.0 |
Immunophenotyping | 181 | 6.0 |
Interleukin-2/pharmacology | 8 | 1.0 |
Lymphocyte Cooperation | 3 | 3.0 |
Receptors, Antigen, B-Cell/immunology | 2 | 8.0 |
Antigens, CD/physiology | 13 | 6.0 |
Antigens, CD80/physiology | 11 | 33.0 |
Cytokines/biosynthesis | 56 | 10.0 |
Isoenzymes/metabolism | 2 | 0.0 |
Membrane Glycoproteins/physiology | 12 | 7.0 |
Phospholipase C/metabolism | 2 | 0.0 |
Cell Culture Techniques/methods | 18 | 8.0 |
Cell Differentiation/drug effects | 57 | 5.0 |
Dendritic Cells/cytology/*drug effects | 2 | 100.0 |
Immunosuppressive Agents/*pharmacology | 21 | 10.0 |
Monocytes/cytology/drug effects | 5 | 14.0 |
Tacrolimus/*pharmacology | 4 | 11.0 |
Antigens, CD/biosynthesis | 55 | 17.0 |
HLA-DR Antigens/biosynthesis | 20 | 20.0 |
Intercellular Adhesion Molecule-1/biosynthesis | 13 | 15.0 |
Interleukin-10/biosynthesis | 18 | 15.0 |
Interleukin-12/biosynthesis | 31 | 31.0 |
Interleukin-8/biosynthesis | 2 | 1.0 |
Lipopolysaccharides/pharmacology | 42 | 4.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 14 | 2.0 |
Receptors, Cell Surface/*physiology | 6 | 2.0 |
Signal Transduction/*immunology | 6 | 1.0 |
Antigens, CD/*immunology | 34 | 7.0 |
Antigens, CD80/*immunology | 23 | 46.0 |
Asthma/*immunology | 10 | 11.0 |
Interferon Type II/*biosynthesis | 11 | 6.0 |
Interleukin-4/*biosynthesis | 6 | 11.0 |
Membrane Glycoproteins/*immunology | 30 | 17.0 |
T-Lymphocytes/*metabolism | 9 | 2.0 |
Cell Differentiation | 81 | 2.0 |
Cell Lineage | 10 | 2.0 |
Cell Survival/drug effects | 10 | 0.0 |
Ligands | 49 | 1.0 |
RNA, Messenger/genetics/metabolism | 8 | 0.0 |
Antigens, CD80/*blood | 7 | 77.0 |
Child | 29 | 0.0 |
Melanoma/*metabolism | 2 | 3.0 |
Monocytes/*metabolism | 11 | 3.0 |
Remission Induction | 2 | 0.0 |
Antigens, CD28/physiology | 9 | 11.0 |
Antigens, Dermatophagoides | 5 | 9.0 |
Chemokines/biosynthesis/genetics | 4 | 22.0 |
Glycoproteins/immunology | 3 | 3.0 |
Hypersensitivity/*immunology | 3 | 6.0 |
Leukocytes, Mononuclear/*physiology | 2 | 8.0 |
Macrophages, Alveolar/*physiology | 3 | 20.0 |
RNA, Messenger/analysis | 20 | 0.0 |
Receptors, Chemokine/genetics | 2 | 4.0 |
Th2 Cells/*immunology | 6 | 4.0 |
Vehicle Emissions/*adverse effects | 2 | 6.0 |
Dendritic Cells/cytology/*drug effects/immunology | 8 | 66.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 55 | 13.0 |
Interleukin-4/pharmacology | 49 | 14.0 |
Leukocytes, Mononuclear/cytology/drug effects/immunology | 2 | 12.0 |
Plant Extracts/*pharmacology | 3 | 4.0 |
*Plant Proteins | 2 | 3.0 |
Toxins/*pharmacology | 2 | 25.0 |
Antigens, CD/*physiology | 14 | 4.0 |
Antigens, CD80/*physiology | 13 | 26.0 |
CD4-Positive T-Lymphocytes/*immunology | 19 | 2.0 |
Dose-Response Relationship, Drug | 24 | 0.0 |
Kinetics | 23 | 0.0 |
*Lymphocyte Activation | 47 | 3.0 |
Membrane Glycoproteins/*physiology | 18 | 6.0 |
Tumor Cells, Cultured | 88 | 0.0 |
Antigens, CD14/*immunology | 2 | 4.0 |
Biological Markers | 25 | 1.0 |
Caco-2 Cells | 2 | 0.0 |
Down-Regulation | 22 | 1.0 |
Escherichia coli/immunology | 4 | 5.0 |
HT29 Cells | 2 | 1.0 |
Leukocytes, Mononuclear/cytology/immunology | 4 | 9.0 |
Lymphocytes/*immunology | 7 | 1.0 |
Receptors, IgG/immunology | 2 | 5.0 |
Aged, 80 and over | 34 | 0.0 |
Chromosome Aberrations | 3 | 0.0 |
DNA, Viral/analysis | 3 | 0.0 |
Dendritic Cells/*pathology | 9 | 24.0 |
HLA-DR Antigens/analysis | 23 | 3.0 |
Karyotyping | 3 | 0.0 |
Tumor Markers, Biological | 3 | 0.0 |
Immunization | 8 | 2.0 |
Leukapheresis | 8 | 7.0 |
Melanoma/immunology/*therapy | 3 | 30.0 |
Membrane Glycoproteins/immunology | 30 | 16.0 |
Peptide Fragments/immunology | 3 | 1.0 |
Alternative Splicing | 4 | 0.0 |
Case-Control Studies | 26 | 0.0 |
Dendritic Cells/metabolism | 3 | 6.0 |
Disease Progression | 8 | 0.0 |
Monocytes/metabolism | 6 | 1.0 |
Solubility | 17 | 1.0 |
Cell Differentiation/*immunology | 5 | 18.0 |
Coculture Techniques | 59 | 8.0 |
Interleukin-10/immunology | 6 | 21.0 |
Tumor Necrosis Factor-alpha/immunology | 7 | 6.0 |
Antibodies, Monoclonal/metabolism | 6 | 1.0 |
Cell Division | 41 | 0.0 |
Endothelium, Vascular/*cytology | 3 | 1.0 |
Interleukin-1/metabolism | 2 | 0.0 |
Interleukin-2/biosynthesis | 14 | 3.0 |
Interleukin-4/biosynthesis | 7 | 4.0 |
Lipopolysaccharides/metabolism | 4 | 3.0 |
Mice, Inbred BALB C | 45 | 1.0 |
Precipitin Tests | 2 | 0.0 |
Protein Binding | 10 | 0.0 |
Proteins/*physiology | 2 | 1.0 |
Tumor Necrosis Factor-alpha/metabolism | 13 | 1.0 |
*Antigen Presentation | 18 | 11.0 |
Infant, Newborn | 16 | 0.0 |
Isoantigens/immunology | 10 | 11.0 |
Th1 Cells/*immunology | 4 | 2.0 |
Antibody Specificity | 6 | 0.0 |
Antigens, CD/immunology | 41 | 8.0 |
Antigens, CD28/*immunology | 10 | 7.0 |
Antigens, CD80/immunology | 25 | 38.0 |
Antigens, Differentiation/*immunology | 3 | 2.0 |
Hematopoietic Stem Cell Transplantation | 5 | 2.0 |
*Immunoconjugates | 85 | 24.0 |
Recombinant Fusion Proteins/immunology | 3 | 2.0 |
Recombinant Proteins/immunology | 9 | 2.0 |
T-Lymphocytes/*immunology | 86 | 3.0 |
Antigens, Differentiation, B-Lymphocyte/*metabolism | 2 | 5.0 |
HLA-DR Antigens/metabolism | 33 | 23.0 |
Immunoglobulin E/biosynthesis | 2 | 5.0 |
Immunoglobulin G/biosynthesis | 3 | 1.0 |
Adenoviridae/*genetics/immunology | 2 | 18.0 |
CD40 Ligand/*immunology | 3 | 33.0 |
Gene Therapy/*methods | 5 | 1.0 |
Transgenes | 5 | 1.0 |
Antigen Presentation | 58 | 19.0 |
Hypersensitivity, Immediate/*immunology | 2 | 7.0 |
Antibodies, Monoclonal/immunology | 19 | 1.0 |
Antigens, CD19/*immunology | 3 | 9.0 |
Antigens, CD3/*immunology | 2 | 1.0 |
*Cytotoxicity, Immunologic | 10 | 2.0 |
Immunotherapy | 10 | 3.0 |
Adjuvants, Immunologic/physiology | 4 | 8.0 |
Allergens/*immunology | 9 | 11.0 |
Antigens, Surface/immunology | 10 | 5.0 |
Cats | 2 | 0.0 |
Cytokines/*immunology | 5 | 5.0 |
Flow Cytometry/methods | 11 | 4.0 |
Glycoproteins/*immunology | 2 | 2.0 |
Up-Regulation/immunology | 23 | 14.0 |
Antigens, CD19/immunology | 2 | 5.0 |
Cell Adhesion | 19 | 1.0 |
Cell Survival | 24 | 2.0 |
Dendritic Cells/*cytology/immunology | 18 | 41.0 |
Dextrans/metabolism | 2 | 9.0 |
Monocytes/*cytology | 17 | 20.0 |
Pinocytosis | 2 | 16.0 |
T-Lymphocytes/cytology/immunology | 10 | 14.0 |
Dendritic Cells/*drug effects/immunology/pathology | 2 | 100.0 |
Phytotherapy | 2 | 7.0 |
Receptors, CCR5/analysis | 3 | 6.0 |
Tumor Necrosis Factor-alpha/analysis | 6 | 1.0 |
Antigens, CD1/metabolism | 10 | 25.0 |
Phagocytosis/*immunology | 2 | 3.0 |
Phenotype | 76 | 0.0 |
Antigens, CD/biosynthesis/*physiology | 2 | 6.0 |
Cell Line | 57 | 0.0 |
Cell Membrane/immunology/metabolism | 4 | 3.0 |
Cytotoxicity Tests, Immunologic | 13 | 3.0 |
Immunity, Cellular/genetics | 2 | 18.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 36 | 0.0 |
Swine | 11 | 0.0 |
Transduction, Genetic | 12 | 3.0 |
CD40 Ligand/*metabolism | 3 | 21.0 |
Cell Movement | 14 | 1.0 |
Dendritic Cells/*drug effects/metabolism | 3 | 37.0 |
Interleukins/*metabolism | 2 | 15.0 |
Protein Conformation | 3 | 0.0 |
Protein Subunits | 2 | 0.0 |
Antigens/immunology | 6 | 4.0 |
Antigens, Differentiation/metabolism | 15 | 12.0 |
Blood Cells | 2 | 5.0 |
Cytokines/pharmacology | 20 | 5.0 |
Dendritic Cells/*cytology/drug effects/immunology | 3 | 30.0 |
Leukocytes, Mononuclear/*cytology | 2 | 9.0 |
Protein Structure, Tertiary/genetics | 2 | 0.0 |
Rats | 16 | 0.0 |
Cell Differentiation/genetics/immunology | 2 | 2.0 |
Dose-Response Relationship, Immunologic | 25 | 4.0 |
Injections, Subcutaneous | 2 | 0.0 |
Lymphocyte Activation/genetics | 5 | 5.0 |
Survival Analysis | 3 | 0.0 |
Up-Regulation/genetics/immunology | 4 | 7.0 |
Cell Communication/*immunology | 8 | 19.0 |
Cell Movement/immunology | 6 | 6.0 |
Clone Cells | 14 | 1.0 |
*Immunologic Memory | 5 | 3.0 |
NF-kappa B/biosynthesis | 2 | 13.0 |
Signal Transduction/immunology | 21 | 6.0 |
Alleles | 2 | 0.0 |
Child, Preschool | 20 | 0.0 |
Genotype | 4 | 0.0 |
Graft Survival | 2 | 0.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Prognosis | 8 | 0.0 |
Prospective Studies | 4 | 0.0 |
Transplantation, Homologous | 8 | 1.0 |
Antigens, Neoplasm/*immunology | 6 | 3.0 |
Cancer Vaccines/*immunology | 3 | 5.0 |
Cytotoxicity, Immunologic | 14 | 1.0 |
Adjuvants, Immunologic/*pharmacology | 15 | 9.0 |
Antigens, CD40/biosynthesis | 17 | 62.0 |
Antigens, CD8/biosynthesis | 2 | 5.0 |
Dendritic Cells/*drug effects/immunology | 8 | 57.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 11 | 7.0 |
Histocompatibility Antigens Class I/biosynthesis | 7 | 14.0 |
Histocompatibility Antigens Class II/biosynthesis | 17 | 38.0 |
Membrane Proteins/*pharmacology | 3 | 6.0 |
Recombinant Proteins/pharmacology | 30 | 1.0 |
Spleen/cytology | 5 | 2.0 |
T-Lymphocytes, Cytotoxic/immunology | 23 | 5.0 |
Dendritic Cells/*drug effects/*immunology | 2 | 100.0 |
Fetal Blood/cytology | 10 | 5.0 |
Leukocytes, Mononuclear/drug effects/immunology | 3 | 6.0 |
Lymphocyte Activation/drug effects/immunology | 3 | 5.0 |
Mice, Inbred DBA | 5 | 1.0 |
Mitogen-Activated Protein Kinase Kinases/metabolism | 2 | 1.0 |
Mitogen-Activated Protein Kinases/metabolism | 7 | 0.0 |
NF-kappa B/metabolism | 17 | 2.0 |
Protein Kinase C/metabolism | 3 | 0.0 |
Antigens, CD14/immunology | 4 | 7.0 |
Antigens, CD3/immunology | 18 | 6.0 |
Antigens, CD40/immunology | 17 | 32.0 |
Intercellular Adhesion Molecule-1/immunology | 9 | 21.0 |
Interferon Type II/immunology | 7 | 7.0 |
Interleukin-10 | 2 | 50.0 |
Leukocytes, Mononuclear/immunology | 13 | 4.0 |
Mycobacterium tuberculosis/*immunology | 2 | 3.0 |
T-Lymphocytes, Cytotoxic/*immunology | 23 | 4.0 |
Tuberculosis, Pulmonary/*immunology | 2 | 5.0 |
Administration, Inhalation | 2 | 1.0 |
Immunotherapy/methods | 6 | 7.0 |
Treatment Failure | 2 | 0.0 |
Treatment Outcome | 10 | 0.0 |
Antigens, CD14/blood | 2 | 6.0 |
Antigens, CD34/*blood | 4 | 5.0 |
Cell Communication/physiology | 3 | 3.0 |
Cell Differentiation/physiology | 6 | 1.0 |
Cell Division/physiology | 5 | 0.0 |
Dendritic Cells/*cytology/drug effects/metabolism | 3 | 100.0 |
Monocytes/cytology/metabolism | 6 | 23.0 |
Skin/*cytology | 2 | 4.0 |
Antigens, CD28/analysis | 7 | 18.0 |
*Bacterial Toxins | 2 | 1.0 |
Enterotoxins/*pharmacology | 2 | 3.0 |
Antigens, CD/*metabolism | 44 | 7.0 |
Antigens, CD28/metabolism | 17 | 18.0 |
Antigens, CD80/*metabolism | 31 | 54.0 |
Antigens, Differentiation, T-Lymphocyte/metabolism | 2 | 1.0 |
Antigens, Surface/metabolism | 7 | 5.0 |
*Blood Proteins | 4 | 5.0 |
Immune Tolerance | 12 | 4.0 |
Membrane Glycoproteins/*metabolism | 36 | 7.0 |
Peptides/metabolism | 3 | 1.0 |
Dendritic Cells/*cytology/drug effects/*immunology | 4 | 40.0 |
Fetal Blood/*cytology/drug effects/*immunology | 2 | 50.0 |
In Vitro | 59 | 0.0 |
Ionophores/pharmacology | 2 | 1.0 |
*Antigens, CD | 18 | 2.0 |
Cell Count | 19 | 1.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Intestinal Mucosa/*immunology | 3 | 3.0 |
Receptors, Cell Surface/*immunology | 3 | 3.0 |
Statistics, Nonparametric | 14 | 1.0 |
Synovial Membrane/*immunology | 3 | 8.0 |
Antigen-Presenting Cells/metabolism | 3 | 16.0 |
Antigens, Surface/*metabolism | 2 | 3.0 |
Cytokines/*pharmacology | 7 | 1.0 |
Fetus | 4 | 0.0 |
Histocompatibility Antigens Class I/metabolism | 4 | 6.0 |
Histocompatibility Antigens Class II/metabolism | 14 | 17.0 |
Intercellular Adhesion Molecule-1/metabolism | 14 | 7.0 |
Antigens, CD28/immunology | 14 | 9.0 |
Haptens/immunology | 2 | 22.0 |
Interferon Type II/metabolism | 12 | 5.0 |
Lymphocyte Activation/*physiology | 3 | 3.0 |
Receptors, Antigen, T-Cell/metabolism | 3 | 1.0 |
Receptors, Interleukin-2/metabolism | 9 | 4.0 |
Endothelium, Vascular/*cytology/physiology | 2 | 10.0 |
Immunohistochemistry | 47 | 0.0 |
Intercellular Adhesion Molecule-1/analysis | 11 | 10.0 |
Antigen-Presenting Cells/immunology | 24 | 8.0 |
CD8-Positive T-Lymphocytes/immunology | 16 | 3.0 |
Cell Aggregation | 4 | 3.0 |
Chronic Disease | 8 | 0.0 |
Epithelial Cells/immunology | 4 | 11.0 |
Fluorescent Antibody Technique, Indirect | 6 | 0.0 |
Histocompatibility Antigens Class II/immunology | 10 | 5.0 |
Langerhans Cells/immunology | 3 | 8.0 |
Lymphocyte Activation/*immunology | 38 | 8.0 |
Microscopy, Electron | 14 | 0.0 |
Periodontitis/*immunology | 2 | 11.0 |
Plasma Cells/immunology | 2 | 7.0 |
Antigens, Differentiation/chemistry/genetics/*metabolism | 2 | 33.0 |
Base Sequence | 52 | 0.0 |
Cell Membrane/immunology | 6 | 2.0 |
Cross-Linking Reagents | 3 | 0.0 |
Interferon-gamma, Recombinant/pharmacology | 4 | 2.0 |
Intracellular Fluid/immunology | 2 | 13.0 |
Monocytes/drug effects/*immunology/metabolism | 2 | 15.0 |
Transcription Factor AP-1/metabolism | 3 | 1.0 |
U937 Cells | 7 | 1.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 2 | 0.0 |
Antigen Presentation/drug effects | 11 | 35.0 |
Antigens, CD40/metabolism | 19 | 29.0 |
Dendritic Cells/cytology/*drug effects/*immunology/metabolism | 3 | 75.0 |
Monocytes/cytology/drug effects/immunology/metabolism | 2 | 50.0 |
Protein-Serine-Threonine Kinases/metabolism | 3 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 5 | 0.0 |
Up-Regulation/drug effects | 9 | 2.0 |
Translocation, Genetic | 2 | 0.0 |
Antigens, CD/genetics/*metabolism | 8 | 8.0 |
Dexamethasone/pharmacology | 3 | 0.0 |
Enzyme Inhibitors/pharmacology | 7 | 0.0 |
Imidazoles/pharmacology | 3 | 1.0 |
JNK Mitogen-Activated Protein Kinases | 5 | 0.0 |
Lipopolysaccharides/*pharmacology | 10 | 2.0 |
Membrane Glycoproteins/genetics/*metabolism | 10 | 6.0 |
Monocytes/drug effects/*immunology | 3 | 4.0 |
Mutation | 6 | 0.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
Pyridines/pharmacology | 3 | 1.0 |
p38 Mitogen-Activated Protein Kinases | 12 | 1.0 |
Antigens, CD/biosynthesis/*immunology | 5 | 25.0 |
Dendritic Cells/immunology/*pathology | 4 | 26.0 |
Membrane Glycoproteins/biosynthesis/*immunology | 5 | 38.0 |
*Tumor Markers, Biological | 2 | 1.0 |
Antigens, Surface/analysis | 2 | 0.0 |
Nitric Oxide/biosynthesis | 3 | 3.0 |
Cell Line, Transformed | 14 | 0.0 |
Cell Separation | 38 | 3.0 |
Cell Transplantation | 3 | 3.0 |
DNA Primers/chemistry | 10 | 0.0 |
RNA, Messenger/metabolism | 25 | 0.0 |
T-Lymphocytes/physiology | 7 | 5.0 |
Transfection | 44 | 0.0 |
Apoptosis | 15 | 0.0 |
Dendritic Cells/*immunology/virology | 5 | 55.0 |
Macrophage Activation | 6 | 3.0 |
Tumor Necrosis Factor-alpha/genetics/metabolism | 3 | 5.0 |
Virus Replication | 11 | 1.0 |
Biological Transport | 4 | 0.0 |
Intestinal Mucosa/*metabolism | 2 | 2.0 |
Models, Biological | 3 | 0.0 |
Antigens, CD/biosynthesis/immunology | 7 | 25.0 |
Cell Differentiation/drug effects/immunology | 25 | 35.0 |
Dendritic Cells/*cytology/*immunology | 6 | 40.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/immunology/pharmacology | 2 | 25.0 |
Monocytes/*cytology/immunology | 3 | 15.0 |
Tumor Necrosis Factor-alpha/pharmacology | 33 | 2.0 |
Antigens, CD | 6 | 4.0 |
Antigens, CD14/analysis | 14 | 11.0 |
B-Lymphocytes/pathology | 2 | 2.0 |
*Cell Communication | 6 | 7.0 |
Antigens, CD80/*biosynthesis | 16 | 43.0 |
Bronchoalveolar Lavage Fluid/cytology | 5 | 4.0 |
Membrane Glycoproteins/*biosynthesis | 21 | 23.0 |
Phytohemagglutinins/pharmacology | 11 | 2.0 |
Antigens, CD1/*biosynthesis | 2 | 20.0 |
CD4-Positive T-Lymphocytes/drug effects/immunology | 4 | 9.0 |
Dextrans/immunology/metabolism | 2 | 66.0 |
Interleukin-10/secretion | 6 | 18.0 |
Interleukin-12/secretion | 14 | 51.0 |
Lymphocyte Activation/drug effects | 19 | 3.0 |
Blood Cells/cytology | 2 | 11.0 |
Cell Size | 2 | 0.0 |
Infant | 9 | 0.0 |
Receptors, IgG/analysis | 2 | 3.0 |
Stem Cells/*cytology | 2 | 2.0 |
Immunity, Cellular | 11 | 1.0 |
Macaca mulatta | 8 | 1.0 |
SIV/*immunology | 2 | 7.0 |
Gene Therapy | 6 | 1.0 |
Genetic Vectors | 14 | 0.0 |
*Immunotherapy | 3 | 1.0 |
*Repressor Proteins | 2 | 0.0 |
Antigens, CD80/analysis | 27 | 55.0 |
Histocompatibility Antigens Class I/analysis | 7 | 7.0 |
Acetylcysteine/pharmacology | 2 | 2.0 |
Antigens, CD/biosynthesis/genetics | 9 | 26.0 |
Cattle | 3 | 0.0 |
Cytokines/biosynthesis/genetics | 6 | 9.0 |
Genes, Reporter | 5 | 0.0 |
RNA, Messenger/biosynthesis | 10 | 0.0 |
Antigens, CD3/physiology | 3 | 4.0 |
CD40 Ligand/biosynthesis | 3 | 27.0 |
Dendritic Cells/cytology/enzymology/*immunology/metabolism | 2 | 100.0 |
Immune Sera/pharmacology | 3 | 3.0 |
Lipid A/*analogs & derivatives/*pharmacology | 2 | 40.0 |
Monocytes/cytology | 15 | 14.0 |
Muromonab-CD3/pharmacology | 5 | 7.0 |
T-Lymphocytes/*immunology/metabolism | 8 | 5.0 |
Bronchoalveolar Lavage Fluid/immunology | 5 | 14.0 |
Disease Models, Animal | 8 | 0.0 |
Eosinophils/*immunology | 2 | 3.0 |
Langerhans Cells/*metabolism | 3 | 15.0 |
Antibodies/pharmacology | 3 | 0.0 |
Antigens, CD/immunology/physiology | 2 | 12.0 |
Antigens, CD34/analysis | 11 | 1.0 |
Dendritic Cells/*immunology/*metabolism | 6 | 35.0 |
Endocytosis | 12 | 3.0 |
*Lectins, C-Type | 13 | 7.0 |
*Mannose-Binding Lectins | 8 | 16.0 |
Monocytes/immunology | 18 | 4.0 |
Antibody Affinity | 2 | 1.0 |
Antigens, CD95/metabolism | 7 | 4.0 |
B-Lymphocyte Subsets/classification/*immunology | 2 | 50.0 |
*Clonal Anergy | 4 | 13.0 |
Immunoglobulin M/blood | 2 | 1.0 |
Lupus Erythematosus, Systemic/*immunology | 4 | 2.0 |
Mice, Transgenic | 16 | 0.0 |
Spleen/immunology | 3 | 1.0 |
Cell Communication | 12 | 4.0 |
Immunologic Surveillance | 2 | 7.0 |
Lymphokines/physiology | 2 | 2.0 |
Transforming Growth Factor beta/physiology | 2 | 2.0 |
Vascular Endothelial Growth Factor A | 4 | 0.0 |
Vascular Endothelial Growth Factors | 4 | 0.0 |
Dendritic Cells/*physiology | 26 | 33.0 |
Immunoglobulins/*analysis | 4 | 4.0 |
Membrane Glycoproteins/*analysis | 11 | 7.0 |
Monocytes/*physiology | 8 | 5.0 |
Antigens, CD28/*physiology | 10 | 10.0 |
Bronchi/*immunology | 2 | 20.0 |
Cytokines/*biosynthesis | 17 | 4.0 |
Adenosine Triphosphate/metabolism/pharmacology | 3 | 27.0 |
Dyes/diagnostic use | 2 | 2.0 |
Gene Expression Regulation/*physiology | 3 | 0.0 |
Antibodies, Monoclonal/pharmacology | 36 | 4.0 |
Antigens, CD/*biosynthesis/genetics/immunology | 3 | 33.0 |
Antigens, Differentiation/pharmacology | 8 | 38.0 |
Membrane Glycoproteins/*biosynthesis/genetics/immunology | 3 | 42.0 |
Tetanus Toxoid/pharmacology | 2 | 8.0 |
Bacterial Infections/immunology | 2 | 8.0 |
Histocompatibility Antigens Class II/*analysis | 3 | 2.0 |
Neutrophils/*immunology | 4 | 2.0 |
Reference Values | 16 | 0.0 |
Wegener's Granulomatosis/*immunology | 3 | 27.0 |
CD4-Positive T-Lymphocytes | 2 | 0.0 |
Proteins/genetics | 2 | 0.0 |
Signal Transduction | 22 | 0.0 |
Syndrome | 3 | 0.0 |
Antigens, CD/drug effects/immunology | 2 | 40.0 |
B-Lymphocytes/drug effects/immunology | 2 | 6.0 |
Immunity, Cellular/drug effects/immunology | 2 | 11.0 |
Membrane Glycoproteins/drug effects/immunology | 2 | 40.0 |
Mice, Knockout | 15 | 0.0 |
Up-Regulation/drug effects/immunology | 8 | 21.0 |
Antigen-Presenting Cells/immunology/*metabolism | 3 | 37.0 |
COS Cells | 3 | 0.0 |
Cercopithecus aethiops | 4 | 0.0 |
Monocytes/cytology/immunology/metabolism | 3 | 21.0 |
Phosphorylation | 15 | 0.0 |
T-Lymphocytes/cytology/immunology/metabolism | 2 | 10.0 |
Tetanus Toxoid/immunology | 8 | 10.0 |
Up-Regulation/*immunology | 5 | 9.0 |
Interferon-alpha/biosynthesis | 4 | 16.0 |
Adjuvants, Immunologic/*administration & dosage | 2 | 6.0 |
Antigens, CD1/analysis | 14 | 18.0 |
Drug Synergism | 14 | 1.0 |
Interferon-beta/*administration & dosage | 2 | 28.0 |
Interleukin-10/analysis/biosynthesis | 2 | 50.0 |
Multiple Sclerosis, Chronic Progressive/*drug therapy/immunology | 3 | 75.0 |
Multiple Sclerosis, Relapsing-Remitting/*drug therapy/immunology | 3 | 50.0 |
Receptors, Interleukin-3/analysis | 2 | 18.0 |
Th2 Cells/cytology/immunology | 3 | 60.0 |
B-Lymphocytes/*metabolism | 4 | 2.0 |
Cross-Linking Reagents/pharmacology | 2 | 1.0 |
Immunoglobulin G/metabolism | 2 | 1.0 |
Membrane Glycoproteins/metabolism/*physiology | 6 | 25.0 |
Membrane Proteins/metabolism | 3 | 0.0 |
Proto-Oncogene Proteins/metabolism | 4 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 2 | 0.0 |
Adjuvants, Immunologic/*metabolism | 2 | 28.0 |
Antigens, CD/drug effects/metabolism | 2 | 18.0 |
Cell Adhesion/drug effects | 2 | 0.0 |
Dextrans/pharmacokinetics | 2 | 40.0 |
Fluorescein-5-isothiocyanate/analogs & derivatives/pharmacokinetics | 2 | 100.0 |
Leukemia, Myeloid/immunology/*pathology | 2 | 22.0 |
Membrane Glycoproteins/drug effects/metabolism | 2 | 28.0 |
Receptors, Cell Surface/metabolism/physiology | 2 | 50.0 |
Tumor Cells, Cultured/drug effects | 5 | 0.0 |
Antigens, CD34/blood | 2 | 3.0 |
Culture Media/chemistry/pharmacology | 2 | 18.0 |
Dendritic Cells/*cytology | 18 | 32.0 |
Hematopoietic Stem Cell Mobilization | 4 | 4.0 |
Autoantigens/immunology | 3 | 2.0 |
Cell Differentiation/immunology | 46 | 14.0 |
Dendritic Cells/*cytology/*immunology/metabolism | 5 | 45.0 |
Phagocytosis | 10 | 2.0 |
Antigen-Presenting Cells/immunology/metabolism | 5 | 23.0 |
Antigens, CD/*biosynthesis/blood/physiology | 2 | 100.0 |
Cell Communication/immunology | 14 | 17.0 |
Interleukin-3/*pharmacology | 2 | 1.0 |
Membrane Glycoproteins/*biosynthesis/blood/physiology | 2 | 66.0 |
Superantigens/pharmacology | 2 | 8.0 |
Antibodies, Monoclonal/*pharmacology | 3 | 1.0 |
Aorta | 5 | 3.0 |
CD4-Positive T-Lymphocytes/cytology/*immunology | 2 | 3.0 |
Cell Adhesion/immunology | 5 | 2.0 |
Endothelium, Vascular/*immunology | 3 | 3.0 |
Lymph Nodes/immunology | 2 | 2.0 |
Lymphocyte Function-Associated Antigen-1/immunology | 2 | 7.0 |
Transplantation, Heterologous/immunology | 2 | 11.0 |
Antigens, Neoplasm/*metabolism | 2 | 2.0 |
Cell Adhesion Molecules/*metabolism | 5 | 1.0 |
Multivariate Analysis | 3 | 0.0 |
Survival Rate | 8 | 0.0 |
Tumor Markers, Biological/*metabolism | 2 | 0.0 |
Dendritic Cells/*immunology/pathology | 2 | 11.0 |
Leukemia, B-Cell, Chronic/*immunology | 3 | 6.0 |
Polymerase Chain Reaction/methods | 3 | 0.0 |
Antigens, CD1/immunology | 2 | 18.0 |
Antigens, CD80/*analysis | 6 | 40.0 |
Langerhans Cells/*immunology | 5 | 12.0 |
Acetylmuramyl-Alanyl-Isoglutamine/*analogs & derivatives/*pharmacology | 2 | 66.0 |
Antigens, CD/*biosynthesis/genetics | 7 | 11.0 |
Cells, Cultured/drug effects | 3 | 3.0 |
Cytokines/*biosynthesis/genetics | 4 | 5.0 |
Dendritic Cells/cytology/*drug effects/immunology/metabolism | 3 | 100.0 |
Gene Expression Regulation/drug effects | 9 | 1.0 |
Genes, MHC Class II | 3 | 1.0 |
HLA-DR Antigens/*biosynthesis | 4 | 13.0 |
Tumor Necrosis Factor-alpha/biosynthesis/genetics | 5 | 8.0 |
Cell Separation/*methods | 2 | 1.0 |
Fetal Blood/*cytology | 9 | 4.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 3 | 2.0 |
Antigens, CD3/metabolism | 7 | 4.0 |
CD4-CD8 Ratio | 4 | 0.0 |
Diagnosis, Differential | 3 | 0.0 |
T-Lymphocyte Subsets/immunology/pathology | 2 | 9.0 |
Antigens, Surface/*biosynthesis | 4 | 16.0 |
Antineoplastic Agents/*pharmacology | 3 | 0.0 |
Cross-Sectional Studies | 3 | 0.0 |
Interferon-beta/*pharmacology | 3 | 5.0 |
Monocytes/*drug effects | 3 | 5.0 |
Multiple Sclerosis/*immunology | 3 | 2.0 |
Antibodies, Monoclonal | 14 | 0.0 |
Fluorescent Antibody Technique | 10 | 0.0 |
Membrane Glycoproteins/immunology/physiology | 2 | 33.0 |
Severity of Illness Index | 5 | 0.0 |
Dendritic Cells/*immunology/metabolism/physiology | 2 | 100.0 |
Genetic Vectors/genetics | 4 | 1.0 |
Green Fluorescent Proteins | 6 | 0.0 |
Histocompatibility Antigens Class I/immunology | 4 | 3.0 |
Immunotherapy, Adoptive | 7 | 9.0 |
Luminescent Proteins/genetics | 2 | 1.0 |
Neoplasms, Experimental/immunology/prevention & control | 2 | 100.0 |
RNA, Messenger/biosynthesis/genetics | 4 | 0.0 |
Antigens, CD1/*metabolism | 2 | 6.0 |
Dendritic Cells/*metabolism | 13 | 20.0 |
Immunoglobulins/analysis | 10 | 4.0 |
Microscopy, Fluorescence | 7 | 0.0 |
Antigens, Differentiation/*biosynthesis | 4 | 12.0 |
B-Lymphocytes/drug effects/*immunology | 4 | 12.0 |
Mitogens/pharmacology | 5 | 1.0 |
T-Lymphocytes/drug effects/*immunology | 13 | 8.0 |
Allergens/*adverse effects | 3 | 27.0 |
Cell Division/immunology | 30 | 10.0 |
Lymphocytes/immunology | 4 | 1.0 |
Pilot Projects | 4 | 0.0 |
Adjuvants, Immunologic/*physiology | 2 | 6.0 |
Down-Regulation/immunology | 11 | 11.0 |
HLA Antigens/analysis | 2 | 0.0 |
Hay Fever/*immunology | 3 | 23.0 |
Interleukin-12/immunology | 2 | 9.0 |
Interleukin-4/immunology | 6 | 10.0 |
Leukocytes, Mononuclear/*immunology | 7 | 4.0 |
Th2 Cells/immunology | 11 | 6.0 |
Colorectal Neoplasms/immunology/therapy | 2 | 50.0 |
Dendritic Cells/*immunology/*virology | 3 | 30.0 |
CD40 Ligand/*pharmacology | 2 | 28.0 |
Cell Movement/drug effects | 5 | 1.0 |
Interleukin-12/*biosynthesis | 4 | 11.0 |
Oligodeoxyribonucleotides/*pharmacology | 5 | 16.0 |
Receptors, Cell Surface/*biosynthesis | 3 | 5.0 |
Receptors, Chemokine/biosynthesis | 7 | 14.0 |
Th1 Cells/immunology | 17 | 10.0 |
Antigens, CD40/physiology | 6 | 20.0 |
Dendritic Cells/drug effects/*physiology | 3 | 37.0 |
Interleukin-12/biosynthesis/genetics | 4 | 50.0 |
Interleukin-6/biosynthesis/genetics | 2 | 5.0 |
Mice, Inbred C3H | 18 | 2.0 |
Mice, SCID | 6 | 0.0 |
RANTES/biosynthesis | 2 | 11.0 |
Th1 Cells/physiology | 2 | 12.0 |
Thiazoles/pharmacology | 2 | 1.0 |
Antigens, Neoplasm/immunology | 10 | 7.0 |
Apoptosis/*drug effects | 6 | 0.0 |
Antigens, CD34 | 9 | 1.0 |
Antigens, Viral/immunology | 3 | 2.0 |
Cell Division/drug effects | 23 | 0.0 |
Leukocytes, Mononuclear/cytology | 5 | 10.0 |
Incidence | 3 | 0.0 |
*Kidney Transplantation | 3 | 0.0 |
Macaca fascicularis | 4 | 1.0 |
Antigens, CD34/*immunology | 3 | 4.0 |
DNA Primers | 11 | 0.0 |
Dendritic Cells/cytology/*immunology | 20 | 33.0 |
Hematopoietic Stem Cells/cytology/*immunology | 4 | 8.0 |
Tumor Necrosis Factor-alpha/*physiology | 3 | 1.0 |
Dendritic Cells/cytology/*immunology/metabolism | 7 | 53.0 |
HLA-DR Antigens/immunology | 10 | 4.0 |
T-Lymphocyte Subsets/immunology | 12 | 3.0 |
Th1 Cells/cytology/immunology | 2 | 33.0 |
Animal Testing Alternatives | 3 | 42.0 |
Fetal Blood | 5 | 3.0 |
Lymphocyte Activation/*drug effects | 10 | 3.0 |
Antigens, CD40/*metabolism | 7 | 14.0 |
Blotting, Western | 13 | 0.0 |
CD40 Ligand/pharmacology | 5 | 19.0 |
Histocompatibility Antigens Class I/*metabolism | 3 | 3.0 |
Antigens, CD/blood | 7 | 2.0 |
Antigens, CD20/analysis | 3 | 6.0 |
Antigens, CD3/analysis | 3 | 1.0 |
Antigens, CD4/analysis | 2 | 0.0 |
Antigens, CD8/analysis | 3 | 1.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 2 | 0.0 |
Fluorescent Antibody Technique, Direct | 3 | 2.0 |
Interleukin-13/pharmacology | 2 | 5.0 |
Stimulation, Chemical | 4 | 0.0 |
Antigens, CD/*genetics/metabolism | 3 | 6.0 |
Antigens, CD80/*genetics/metabolism | 2 | 33.0 |
Interferon Type II/*pharmacology | 5 | 1.0 |
Membrane Glycoproteins/*genetics/metabolism | 3 | 4.0 |
CD4 Lymphocyte Count | 5 | 0.0 |
HIV Antibodies/blood | 2 | 2.0 |
Integrin alphaXbeta2/metabolism | 2 | 25.0 |
RNA, Viral/blood | 2 | 0.0 |
Bone Marrow Cells/immunology | 2 | 5.0 |
Microscopy, Confocal | 13 | 1.0 |
NF-kappa B/physiology | 2 | 2.0 |
Receptors, Cell Surface/deficiency/genetics/*physiology | 2 | 13.0 |
Specific Pathogen-Free Organisms | 2 | 2.0 |
Transcription, Genetic | 11 | 0.0 |
Antigens, CD/biosynthesis/genetics/immunology | 3 | 60.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Membrane Glycoproteins/biosynthesis/genetics/immunology | 2 | 66.0 |
Rabbits | 3 | 0.0 |
Recombinant Fusion Proteins/pharmacology | 2 | 2.0 |
Tuberculin/immunology | 5 | 8.0 |
Leukemia, Myeloid/*pathology | 2 | 3.0 |
Risk Factors | 2 | 0.0 |
Endocytosis/drug effects | 7 | 11.0 |
Phosphorylation/drug effects | 2 | 0.0 |
Antigens, CD/*analysis | 18 | 2.0 |
Antigens, CD34/*analysis | 4 | 1.0 |
Culture Media, Serum-Free | 8 | 2.0 |
Dendritic Cells/chemistry/cytology/*immunology | 2 | 100.0 |
Ionomycin/pharmacology | 6 | 2.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 4 | 1.0 |
Antigens, CD/*biosynthesis/*immunology | 2 | 66.0 |
Antigens, CD80/biosynthesis/immunology | 2 | 50.0 |
Immunophenotyping/methods | 3 | 6.0 |
Membrane Glycoproteins/biosynthesis/immunology | 2 | 16.0 |
Biological Markers/analysis | 9 | 1.0 |
Calcimycin/*pharmacology | 4 | 13.0 |
Calcium/*metabolism | 2 | 0.0 |
Ionophores/*pharmacology | 3 | 15.0 |
Cloning, Molecular | 17 | 0.0 |
In Situ Hybridization, Fluorescence | 11 | 0.0 |
Molecular Sequence Data | 62 | 0.0 |
Polymerase Chain Reaction | 17 | 0.0 |
Cyclosporine/*pharmacology | 5 | 4.0 |
Dendritic Cells/*drug effects/physiology | 6 | 50.0 |
Isoantigens/*immunology | 4 | 5.0 |
Blood | 4 | 2.0 |
Gene Expression Regulation/drug effects/immunology | 2 | 5.0 |
Hematopoietic Stem Cells/cytology/*drug effects | 2 | 3.0 |
Monocytes/cytology/*drug effects | 3 | 23.0 |
Calcitriol/*pharmacology | 2 | 1.0 |
Cell Differentiation/*drug effects | 6 | 3.0 |
Transforming Growth Factor beta/biosynthesis | 4 | 8.0 |
Antigens, CD14/*analysis | 5 | 11.0 |
HLA-DR Antigens/*analysis | 4 | 2.0 |
Histocytochemistry | 3 | 0.0 |
Oxidation-Reduction | 3 | 0.0 |
Receptors, IgG/*analysis | 2 | 6.0 |
*Cell Differentiation | 3 | 1.0 |
Chemotaxis | 2 | 1.0 |
Membrane Glycoproteins/immunology/*metabolism | 8 | 19.0 |
Oxygen/metabolism | 2 | 0.0 |
Influenza A Virus, Human/*immunology | 2 | 6.0 |
Antibody Formation/drug effects | 2 | 4.0 |
Drug Therapy, Combination | 3 | 0.0 |
Lymphocytes/pathology | 2 | 2.0 |
RNA/analysis | 2 | 0.0 |
Safety | 2 | 1.0 |
Tissue Donors | 2 | 0.0 |
Adjuvants, Immunologic | 6 | 11.0 |
B-Lymphocytes/immunology/metabolism | 4 | 7.0 |
Killer Cells, Natural/immunology | 4 | 0.0 |
Mice, Inbred Strains | 2 | 0.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 3 | 1.0 |
Antigens, CD80/biosynthesis/metabolism | 2 | 66.0 |
Cytokines/secretion | 5 | 6.0 |
*Immune Tolerance | 5 | 2.0 |
Macrophages, Peritoneal/drug effects/*immunology | 2 | 28.0 |
Cytokines/biosynthesis/drug effects | 2 | 15.0 |
Dendritic Cells/cytology/drug effects/*immunology | 8 | 36.0 |
Mites/immunology | 2 | 5.0 |
T-Lymphocytes, Helper-Inducer/immunology | 3 | 1.0 |
Amino Acid Sequence | 39 | 0.0 |
Antigens, CD/*genetics | 8 | 3.0 |
Antigens, CD80/*genetics | 11 | 37.0 |
Membrane Glycoproteins/*genetics | 10 | 2.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Sequence Homology, Amino Acid | 11 | 0.0 |
Antigens, CD/analysis/genetics | 2 | 6.0 |
Nicotine/*pharmacology | 2 | 7.0 |
Antigens, CD14/*metabolism | 3 | 3.0 |
Interleukin-10/*metabolism | 3 | 10.0 |
Interleukin-4/*metabolism | 2 | 5.0 |
Receptors, IgG/*metabolism | 3 | 4.0 |
Dendritic Cells/cytology/drug effects/*metabolism | 2 | 40.0 |
Antigen-Presenting Cells/drug effects/*immunology | 3 | 33.0 |
Clonal Anergy/*immunology | 4 | 16.0 |
Dendritic Cells/drug effects/*immunology | 10 | 38.0 |
Interleukin-12/immunology/secretion | 2 | 66.0 |
Lipopolysaccharides/immunology | 5 | 4.0 |
Antigens, CD40/*immunology | 5 | 13.0 |
Endocytosis/immunology | 8 | 36.0 |
HIV Envelope Protein gp120/*immunology | 3 | 2.0 |
Monocytes/cytology/*immunology | 7 | 20.0 |
Receptors, Chemokine/immunology | 4 | 12.0 |
Membrane Glycoproteins/genetics | 7 | 3.0 |
*Up-Regulation | 4 | 1.0 |
Cytokines/analysis | 6 | 8.0 |
Dendritic Cells/*cytology/physiology | 3 | 60.0 |
Interferon Type I/*pharmacology | 2 | 4.0 |
Allergens/administration & dosage | 2 | 13.0 |
Cell-Free System/immunology | 3 | 17.0 |
Homeodomain Proteins/genetics | 2 | 0.0 |
Hyperplasia | 2 | 0.0 |
Injections, Intraperitoneal | 2 | 1.0 |
Dendritic Cells/*cytology/*drug effects/immunology/metabolism | 2 | 100.0 |
T-Lymphocytes, Cytotoxic/immunology/metabolism | 2 | 14.0 |
Lectins | 2 | 2.0 |
Tumor Necrosis Factor-alpha/physiology | 3 | 1.0 |
Antigens, CD/immunology/*metabolism | 6 | 12.0 |
Antigens, CD80/immunology/*metabolism | 5 | 50.0 |
Mutation/genetics | 2 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Surface Plasmon Resonance | 2 | 1.0 |
B-Lymphocytes/*physiology | 2 | 1.0 |
Lymph Nodes/*cytology | 2 | 20.0 |
T-Lymphocytes/*physiology | 5 | 1.0 |
Antigen Presentation/*immunology | 13 | 14.0 |
Apoptosis/immunology | 6 | 6.0 |
Immune Tolerance/immunology | 3 | 6.0 |
Interleukin-6/biosynthesis | 3 | 1.0 |
NF-kappa B/*immunology | 3 | 33.0 |
Oligopeptides/*pharmacology | 2 | 2.0 |
Receptors, IgE/metabolism | 7 | 21.0 |
Interleukin-10/metabolism | 7 | 10.0 |
Interleukin-12/metabolism | 12 | 23.0 |
Monocytes/drug effects/immunology | 3 | 7.0 |
Interferon Type II/secretion | 13 | 12.0 |
Interleukin-10/*pharmacology | 7 | 7.0 |
Interleukin-4/secretion | 5 | 12.0 |
Adenoviridae/genetics | 5 | 1.0 |
Interleukin-4/metabolism | 7 | 7.0 |
Leukocytes, Mononuclear | 4 | 8.0 |
Lymphocyte Subsets | 3 | 1.0 |
Antigens, Viral/analysis | 2 | 2.0 |
Dendritic Cells/immunology/*virology | 2 | 20.0 |
Interleukin-12/analysis | 4 | 36.0 |
Plasmids/genetics | 5 | 1.0 |
Signal Transduction/physiology | 3 | 0.0 |
Cytokines/metabolism | 16 | 3.0 |
K562 Cells | 5 | 1.0 |
Killer Cells, Lymphokine-Activated/*immunology | 2 | 2.0 |
Analysis of Variance | 4 | 0.0 |
Leukocytes/*metabolism | 2 | 2.0 |
Dendritic Cells/*virology | 4 | 28.0 |
Genes, Viral | 2 | 0.0 |
T-Lymphocytes/*virology | 2 | 3.0 |
Histocompatibility Antigens Class II/*metabolism | 3 | 5.0 |
Virion/*metabolism | 2 | 9.0 |
Antigens, CD1/biosynthesis | 8 | 50.0 |
*Immunophenotyping | 6 | 3.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 4 | 2.0 |
Fluorescence | 3 | 1.0 |
Immunophenotyping/*methods | 2 | 2.0 |
Lymphocyte Count | 6 | 0.0 |
Antigens, CD3/pharmacology | 2 | 12.0 |
Glucocorticoids/pharmacology | 4 | 3.0 |
Interleukin-1/pharmacology | 4 | 0.0 |
Major Histocompatibility Complex/*immunology | 2 | 5.0 |
Carrier Proteins/metabolism | 3 | 0.0 |
DNA-Binding Proteins/metabolism | 4 | 0.0 |
Hodgkin Disease/*pathology | 2 | 16.0 |
Receptors, Cell Surface/metabolism | 7 | 1.0 |
Transcription Factors/metabolism | 3 | 0.0 |
Antigens, CD1/*analysis | 2 | 9.0 |
Adjuvants, Immunologic/pharmacology | 6 | 6.0 |
Dendritic Cells/*immunology/*metabolism/pathology | 2 | 100.0 |
Integrins/biosynthesis | 2 | 8.0 |
Interleukin-12/*biosynthesis/secretion | 2 | 66.0 |
Receptors, IgG/metabolism | 4 | 5.0 |
Antigens, CD14 | 3 | 1.0 |
Antigen-Presenting Cells/cytology/*immunology | 2 | 40.0 |
CD40 Ligand/immunology | 3 | 27.0 |
Membrane Glycoproteins/biosynthesis/genetics | 5 | 10.0 |
Transplantation Immunology/*immunology | 2 | 28.0 |
Transplantation, Heterologous | 2 | 0.0 |
3T3 Cells | 3 | 0.0 |
Antigens, CD14/biosynthesis | 12 | 19.0 |
Antigens, CD45/biosynthesis | 2 | 3.0 |
Lymphocytes/metabolism | 2 | 0.0 |
Dendritic Cells/immunology/*physiology | 3 | 42.0 |
Fetal Blood/*immunology | 4 | 5.0 |
Integrin alphaXbeta2/analysis | 6 | 40.0 |
Monocytes/drug effects/physiology | 2 | 11.0 |
Antigens, Differentiation/analysis | 8 | 2.0 |
Chemokines/analysis | 2 | 25.0 |
Cytoplasm/ultrastructure | 2 | 3.0 |
Immunoenzyme Techniques | 10 | 0.0 |
Macrophages/pathology | 2 | 1.0 |
Periodontitis/*immunology/pathology | 2 | 28.0 |
T-Lymphocytes/pathology | 5 | 4.0 |
Cytokines/*metabolism | 5 | 1.0 |
Interleukin-6/metabolism | 4 | 1.0 |
Leukocyte Count | 9 | 0.0 |
Monocytes/drug effects/*metabolism | 3 | 2.0 |
*Renal Dialysis | 2 | 0.0 |
International Cooperation | 2 | 2.0 |
Antigens, CD/immunology/metabolism | 7 | 13.0 |
Antigens, CD80/immunology/metabolism | 3 | 33.0 |
Cell Culture Techniques/*methods | 10 | 10.0 |
Cell Line, Tumor | 16 | 0.0 |
Cell Proliferation/drug effects | 3 | 3.0 |
Membrane Glycoproteins/immunology/metabolism | 6 | 20.0 |
Dendritic Cells/*immunology/metabolism/virology | 2 | 33.0 |
Ebola-like Viruses/*immunology | 2 | 66.0 |
Receptors, Chemokine/analysis | 3 | 10.0 |
Cell Death | 2 | 0.0 |
Dendritic Cells/*immunology/metabolism | 7 | 15.0 |
Recombinant Proteins/biosynthesis/genetics | 2 | 2.0 |
Phagocytosis/immunology | 7 | 10.0 |
T-Lymphocytes, Suppressor-Effector/*immunology | 2 | 2.0 |
Apoptosis/*genetics | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 4 | 0.0 |
Antigens, Neoplasm | 3 | 7.0 |
Leukemia, Myeloid/*immunology/pathology | 3 | 21.0 |
DNA-Binding Proteins/genetics/metabolism | 2 | 0.0 |
*I-kappa B | 2 | 1.0 |
Antibodies, Blocking | 2 | 16.0 |
DNA Primers/genetics | 7 | 0.0 |
Tumor Virus Infections/immunology | 2 | 33.0 |
Cell Membrane/metabolism | 3 | 0.0 |
Dendritic Cells/*cytology/metabolism | 2 | 28.0 |
Antigens, CD/*biosynthesis/blood | 2 | 16.0 |
Membrane Glycoproteins/blood | 4 | 13.0 |
Kidney/*immunology | 2 | 14.0 |
Cell Lineage/immunology | 3 | 10.0 |
Cell Movement/*immunology | 3 | 4.0 |
DNA-Binding Proteins/genetics/*physiology | 2 | 0.0 |
*Gene Therapy | 3 | 0.0 |
Immunologic Memory/immunology | 4 | 10.0 |
Phosphoproteins/genetics/*physiology | 2 | 5.0 |
Receptors, Estrogen/genetics | 2 | 3.0 |
Inflammation | 2 | 0.0 |
Receptors, Melanocortin | 3 | 3.0 |
Skin Diseases/*immunology | 2 | 9.0 |
alpha-MSH/*immunology | 2 | 100.0 |
Interleukin-10/analysis | 3 | 8.0 |
Fluorescent Dyes | 2 | 0.0 |
Apoptosis/physiology | 2 | 0.0 |
HIV-1/pathogenicity/*physiology | 2 | 7.0 |
*Virus Replication | 3 | 1.0 |
Antigens, CD14/metabolism | 7 | 5.0 |
HLA-DR Antigens/blood | 6 | 10.0 |
Interferon Type II/pharmacology | 21 | 3.0 |
Intracellular Fluid/immunology/metabolism | 3 | 10.0 |
Protein Binding/immunology | 11 | 5.0 |
Th1 Cells/immunology/metabolism | 2 | 5.0 |
Trans-Activators/metabolism | 2 | 0.0 |
Tumor Necrosis Factor-alpha/secretion | 6 | 5.0 |
Blotting, Northern | 4 | 0.0 |
RNA, Messenger/*analysis | 4 | 0.0 |
Tissue Distribution | 3 | 0.0 |
Administration, Topical | 3 | 2.0 |
Antigens, CD34/metabolism | 2 | 0.0 |
Dendritic Cells/cytology/immunology | 5 | 50.0 |
Hematopoietic Stem Cells/*immunology | 5 | 3.0 |
Monocytes/cytology/immunology | 10 | 28.0 |
Interleukin-10/pharmacology | 8 | 11.0 |
Autoimmunity/*immunology | 2 | 4.0 |
Clinical Trials | 3 | 0.0 |
Diabetes Mellitus, Type 1/immunology | 3 | 17.0 |
Macromolecular Substances | 2 | 0.0 |
Mice, Inbred NOD | 7 | 3.0 |
Self Tolerance/immunology | 2 | 25.0 |
Interleukin-12/antagonists & inhibitors/biosynthesis | 3 | 42.0 |
Leukocytes/metabolism | 4 | 2.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Th1 Cells/metabolism | 2 | 7.0 |
Th2 Cells/metabolism | 2 | 4.0 |
Adenoviridae/*genetics | 3 | 1.0 |
*Gene Transfer Techniques | 5 | 1.0 |
*Transduction, Genetic | 4 | 5.0 |
Cell Adhesion Molecules/biosynthesis | 3 | 3.0 |
Dendritic Cells/*immunology/*transplantation | 2 | 66.0 |
Injections, Intradermal | 2 | 4.0 |
T-Lymphocytes/immunology/metabolism | 6 | 4.0 |
Dendritic Cells/*cytology/immunology/secretion | 2 | 66.0 |
Immunoassay | 2 | 0.0 |
Signal Transduction/drug effects | 3 | 0.0 |
Structure-Activity Relationship | 4 | 0.0 |
Leukemia, Myeloid/drug therapy/immunology/*pathology | 2 | 100.0 |
Membrane Glycoproteins/analysis/*biosynthesis | 3 | 25.0 |
Antigens, CD19/metabolism | 2 | 8.0 |
Immunity, Natural | 4 | 1.0 |
Stem Cells/cytology/immunology | 3 | 16.0 |
Antigens, CD/biosynthesis/metabolism | 2 | 18.0 |
Antigens, Differentiation, Myelomonocytic/biosynthesis | 4 | 8.0 |
Antigens, Surface/biosynthesis | 8 | 13.0 |
Macrophages/metabolism | 4 | 1.0 |
Endothelial Growth Factors/pharmacology | 2 | 1.0 |
Lymphokines/pharmacology | 3 | 1.0 |
Monocytes/cytology/drug effects/*metabolism | 2 | 22.0 |
Signal Transduction/genetics/immunology | 3 | 3.0 |
B-Lymphocytes/*immunology/pathology | 3 | 7.0 |
Lymphoma, B-Cell/*immunology | 2 | 5.0 |
Polymorphism, Single Nucleotide | 4 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Immunoglobulins/immunology/metabolism | 2 | 33.0 |
Phagocytosis/drug effects | 5 | 5.0 |
Antigens, CD28/*metabolism | 14 | 13.0 |
Antigens, Differentiation/*metabolism | 14 | 11.0 |
CHO Cells | 23 | 1.0 |
Hamsters | 28 | 0.0 |
Interleukin-2/physiology | 3 | 3.0 |
Antibodies, Monoclonal/genetics/*immunology | 2 | 22.0 |
Cross Reactions | 3 | 0.0 |
Leukocytes/immunology | 3 | 2.0 |
Apoptosis/drug effects | 8 | 1.0 |
In Situ Nick-End Labeling | 3 | 0.0 |
Capsules | 2 | 4.0 |
Cytokines/*secretion | 2 | 3.0 |
Drug Carriers | 2 | 1.0 |
Particle Size | 2 | 0.0 |
Plasmids | 3 | 0.0 |
Antineoplastic Agents/*therapeutic use | 2 | 0.0 |
Chemokines/metabolism | 4 | 5.0 |
Combined Modality Therapy | 2 | 0.0 |
Dendritic Cells/immunology/*metabolism | 3 | 17.0 |
Membrane Glycoproteins/genetics/*physiology | 2 | 2.0 |
Anti-Inflammatory Agents/pharmacology | 2 | 3.0 |
Tacrolimus Binding Protein 1A/physiology | 2 | 100.0 |
Antigens, CD27/analysis | 2 | 11.0 |
CD40 Ligand/physiology | 5 | 38.0 |
Proto-Oncogene Proteins c-bcl-2/analysis | 2 | 1.0 |
Antigen Presentation/physiology | 2 | 16.0 |
Cell Adhesion Molecules/metabolism | 5 | 2.0 |
Phagocytosis/physiology | 2 | 6.0 |
Graft vs Host Disease/etiology | 2 | 3.0 |
Chemotaxis, Leukocyte/*immunology | 2 | 4.0 |
Culture Media, Conditioned/pharmacology | 7 | 3.0 |
Tumor Cells, Cultured/*immunology | 2 | 9.0 |
Antigens, CD40/immunology/metabolism | 2 | 28.0 |
Transplantation, Homologous/immunology | 3 | 7.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
Antigens, CD80/biosynthesis/genetics | 3 | 60.0 |
Hematopoietic Stem Cells/*cytology/drug effects | 2 | 2.0 |
Membrane Proteins/pharmacology | 5 | 11.0 |
Monocytes/*cytology/drug effects | 5 | 31.0 |
Antibodies, Monoclonal/immunology/pharmacology | 6 | 6.0 |
Antigens, CD/analysis/immunology | 7 | 14.0 |
Interleukins/secretion | 2 | 25.0 |
Myelodysplastic Syndromes/immunology/pathology | 2 | 66.0 |
Cyclic AMP/metabolism | 2 | 0.0 |
Cytokines/antagonists & inhibitors/biosynthesis | 4 | 23.0 |
Inflammation/immunology | 3 | 2.0 |
Intracellular Fluid/metabolism | 2 | 1.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/secretion | 2 | 15.0 |
Antigens, CD40/analysis/*physiology | 2 | 66.0 |
Antigens, CD95/*metabolism | 3 | 2.0 |
*Apoptosis | 4 | 0.0 |
Calcium/metabolism | 7 | 0.0 |
Dendritic Cells | 2 | 13.0 |
Staining and Labeling/methods | 2 | 1.0 |
Tetradecanoylphorbol Acetate/pharmacology | 13 | 0.0 |
Interleukin-4/*pharmacology | 8 | 3.0 |
CD4-Positive T-Lymphocytes/cytology/immunology | 2 | 3.0 |
Gene Expression/immunology | 3 | 3.0 |
Dendritic Cells/*immunology/transplantation | 2 | 50.0 |
Neoplasm Metastasis | 5 | 0.0 |
Binding Sites, Antibody | 3 | 0.0 |
Monocytes/immunology/metabolism | 2 | 4.0 |
Immunity, Cellular/physiology | 2 | 16.0 |
Sensitivity and Specificity | 7 | 0.0 |
Gene Transfer Techniques | 6 | 1.0 |
Graft Rejection/*immunology | 3 | 3.0 |
Mice, Nude | 4 | 0.0 |
Neoplasm Transplantation | 6 | 0.0 |
Superantigens/immunology | 3 | 6.0 |
T-Lymphocytes/cytology/drug effects/immunology | 2 | 22.0 |
Interleukin-4/therapeutic use | 2 | 28.0 |
Cryopreservation | 6 | 5.0 |
Culture Media | 13 | 1.0 |
*Dendritic Cells | 2 | 18.0 |
Stem Cell Factor/pharmacology | 6 | 4.0 |
Transforming Growth Factor beta/pharmacology | 2 | 0.0 |
Antigens, CD80/blood | 4 | 100.0 |
Cytokines/*blood | 2 | 0.0 |
Neoplasms/immunology/*therapy | 2 | 3.0 |
Interleukin-2/*biosynthesis | 3 | 2.0 |
Tyrosine/metabolism | 2 | 0.0 |
Antigens, CD/metabolism/*physiology | 2 | 7.0 |
Interferon Type II/*metabolism | 3 | 4.0 |
Interleukin-12/pharmacology | 2 | 4.0 |
Monocytes/drug effects/immunology/metabolism | 2 | 10.0 |
DNA-Binding Proteins/*physiology | 2 | 0.0 |
NF-kappa B/*physiology | 2 | 2.0 |
*Nuclear Proteins | 4 | 0.0 |
Transcription Factors/*physiology | 2 | 0.0 |
Dendritic Cells/*cytology/*drug effects/immunology | 2 | 40.0 |
Dexamethasone/*pharmacology | 5 | 2.0 |
Glucocorticoids/*pharmacology | 2 | 1.0 |
Isoantigens | 3 | 11.0 |
Transcription, Genetic/drug effects | 2 | 0.0 |
CD4-Positive T-Lymphocytes/virology | 2 | 2.0 |
*HIV-1 | 2 | 0.0 |
Macrophages/immunology | 4 | 1.0 |
DNA, Bacterial/*immunology | 2 | 40.0 |
Deoxyribonucleases/pharmacology | 2 | 25.0 |
HLA-D Antigens/biosynthesis | 2 | 18.0 |
Oligodeoxyribonucleotides/*immunology | 2 | 22.0 |
Species Specificity | 9 | 0.0 |
T-Lymphocytes/*immunology/secretion | 3 | 37.0 |
Th1 Cells/immunology/secretion | 2 | 18.0 |
Molecular Weight | 4 | 0.0 |
RNA, Messenger | 2 | 0.0 |
Influenza Vaccines/*immunology | 2 | 10.0 |
Intercellular Adhesion Molecule-1/*metabolism | 3 | 5.0 |
Spleen/cytology/immunology | 3 | 4.0 |
Antigens, CD45/analysis | 5 | 1.0 |
Cadaver | 2 | 0.0 |
Receptors, Cell Surface/genetics | 2 | 1.0 |
Biopsy | 6 | 0.0 |
Homeostasis/*immunology | 2 | 28.0 |
Luminescent Proteins/biosynthesis/genetics | 2 | 8.0 |
Monocytes/*immunology/*metabolism | 2 | 13.0 |
Dendritic Cells/drug effects/*immunology/metabolism | 3 | 50.0 |
Haptens/*immunology | 2 | 25.0 |
Sodium Dodecyl Sulfate/pharmacology | 3 | 13.0 |
Neoplasm Staging | 3 | 0.0 |
*Cancer Vaccines | 4 | 15.0 |
Liposomes | 2 | 0.0 |
Transfection/*methods | 2 | 3.0 |
Cytokines/*analysis | 4 | 4.0 |
Interferon Type II/analysis | 4 | 4.0 |
Interleukin-1/analysis | 3 | 3.0 |
Interleukin-2/analysis | 3 | 7.0 |
Interleukin-6/analysis | 2 | 2.0 |
HIV-1/*immunology | 8 | 1.0 |
Hybrid Cells | 2 | 0.0 |
T-Lymphocytes, Cytotoxic/*immunology/virology | 2 | 22.0 |
Culture Media/pharmacology | 2 | 2.0 |
Dendritic Cells/*cytology/immunology/physiology | 3 | 75.0 |
Hematopoietic Stem Cells/cytology | 2 | 2.0 |
Antigens, CD/genetics/*immunology | 6 | 16.0 |
Antigens, CD80/genetics/*immunology | 8 | 44.0 |
Membrane Glycoproteins/genetics/*immunology | 8 | 15.0 |
Antigens, CD80/*metabolism/physiology | 3 | 100.0 |
Cytopathogenic Effect, Viral | 2 | 1.0 |
Disease Susceptibility | 2 | 0.0 |
HIV Seronegativity | 3 | 2.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/immunology | 4 | 14.0 |
HLA-D Antigens/*immunology | 2 | 3.0 |
Lymphocytes/cytology | 3 | 3.0 |
Hematopoietic Stem Cells/drug effects | 2 | 3.0 |
Culture Media, Conditioned | 5 | 1.0 |
Ultraviolet Rays/*adverse effects | 3 | 6.0 |
Immunoglobulin D/analysis | 3 | 13.0 |
Cell Proliferation | 4 | 2.0 |
Drug Combinations | 2 | 0.0 |
Bone Marrow Cells/*metabolism | 2 | 4.0 |
Antigens, CD11c/biosynthesis | 2 | 50.0 |
Membrane Glycoproteins/biosynthesis/metabolism | 2 | 28.0 |
Arthritis, Rheumatoid/*immunology | 5 | 2.0 |
Interleukin-1/biosynthesis | 3 | 1.0 |
Receptors, Tumor Necrosis Factor, Type I | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*antagonists & inhibitors/physiology | 2 | 11.0 |
Receptors, IgG/*immunology | 2 | 6.0 |
Hematopoietic Stem Cells/cytology/immunology | 2 | 6.0 |
Human T-lymphotropic virus 1/*immunology | 2 | 10.0 |
Cell Separation/methods | 9 | 5.0 |
Culture Media/chemistry | 2 | 5.0 |
Neoplasms/immunology/therapy | 3 | 17.0 |
Monocytes/*cytology/drug effects/metabolism | 2 | 33.0 |
Mice, Inbred CBA | 3 | 0.0 |
Protein Engineering | 2 | 2.0 |
CD40 Ligand | 35 | 20.0 |
Endothelium, Vascular/cytology/physiology | 2 | 10.0 |
Transplantation, Heterologous/*immunology | 2 | 3.0 |
Cancer Vaccines/immunology/therapeutic use | 3 | 50.0 |
Protein Biosynthesis | 2 | 0.0 |
Mitogen-Activated Protein Kinases/*physiology | 2 | 2.0 |
*Signal Transduction | 3 | 0.0 |
Antigens, CD28/genetics/*metabolism | 2 | 14.0 |
Antigens, CD80/genetics/*metabolism | 8 | 57.0 |
Antigens, Differentiation/genetics/*metabolism | 2 | 8.0 |
Antigens, CD/genetics | 6 | 4.0 |
Immunoglobulin G/pharmacology | 2 | 3.0 |
Up-Regulation/*drug effects | 2 | 2.0 |
Antigens, CD/genetics/immunology | 3 | 15.0 |
Cyclosporine/pharmacology | 6 | 2.0 |
Immunosuppressive Agents/pharmacology | 17 | 10.0 |
Interleukin-13/*biosynthesis | 2 | 33.0 |
Membrane Glycoproteins/genetics/immunology | 3 | 14.0 |
Synovial Fluid/*immunology | 3 | 5.0 |
Receptors, Cell Surface/physiology | 2 | 1.0 |
Antigens, CD28/biosynthesis/*immunology | 2 | 50.0 |
Antigens, CD80/biosynthesis/*immunology | 6 | 66.0 |
Antigens, Differentiation/biosynthesis/*immunology | 2 | 50.0 |
Liver Transplantation/*immunology | 2 | 6.0 |
T-Lymphocyte Subsets/*immunology/*metabolism | 2 | 7.0 |
Antigens, CD/analysis/metabolism | 2 | 14.0 |
Dendritic Cells/*drug effects/immunology/metabolism | 2 | 33.0 |
Intercellular Adhesion Molecule-1/*genetics | 2 | 8.0 |
Allergens/immunology | 4 | 5.0 |
Antigens, CD45/metabolism | 2 | 2.0 |
Bronchoalveolar Lavage Fluid/cytology/immunology | 2 | 5.0 |
CD8-Positive T-Lymphocytes/*immunology/metabolism | 4 | 16.0 |
Gene Library | 2 | 0.0 |
Protein Folding | 3 | 0.0 |
Antigens, Neoplasm/biosynthesis/genetics/immunology | 2 | 100.0 |
Killer Cells, Lymphokine-Activated/immunology | 2 | 3.0 |
Lymphocytes, Tumor-Infiltrating/immunology | 3 | 8.0 |
Tumor Stem Cells/*immunology | 2 | 8.0 |
Down-Regulation/drug effects | 2 | 0.0 |
Gene Expression Regulation/immunology | 6 | 3.0 |
Lymphocyte Subsets/immunology | 3 | 2.0 |
Gene Expression Regulation, Neoplastic/physiology | 2 | 1.0 |
Immune Tolerance/genetics/immunology | 2 | 25.0 |
Alkaline Phosphatase/analysis | 2 | 3.0 |
Antigens, CD45/immunology | 3 | 4.0 |
HLA-DR Antigens/*immunology | 4 | 3.0 |
Osteoblasts/*immunology | 2 | 66.0 |
Mitogen-Activated Protein Kinases/*metabolism | 2 | 0.0 |
T-Lymphocytes/cytology | 6 | 6.0 |
Up-Regulation/radiation effects | 2 | 15.0 |
Protein Subunits/metabolism | 2 | 4.0 |
Apoptosis/*drug effects/immunology | 2 | 15.0 |
Cell Division/drug effects/immunology | 6 | 9.0 |
Growth Inhibitors/*pharmacology | 2 | 1.0 |
Monocytes/cytology/*drug effects/immunology | 3 | 42.0 |
Antigens/metabolism | 2 | 3.0 |
Immune Tolerance/drug effects | 2 | 7.0 |
T-Lymphocytes/drug effects/immunology | 5 | 5.0 |
Cell Differentiation/drug effects/*immunology | 2 | 25.0 |
Toremifene/*pharmacology | 2 | 50.0 |
Antigens, CD58/biosynthesis | 2 | 28.0 |
Mutagenesis, Site-Directed | 8 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Blood Cells/immunology | 2 | 6.0 |
Cell Movement/physiology | 2 | 0.0 |
Antigens, CD11/analysis | 3 | 10.0 |
Fluorescein-5-isothiocyanate | 2 | 1.0 |
Macrophages, Alveolar/*immunology | 3 | 7.0 |
Membrane Glycoproteins/analysis/immunology | 2 | 20.0 |
DNA, Complementary | 6 | 0.0 |
Interleukin-10/*secretion | 2 | 18.0 |
Interleukin-7/*pharmacology | 2 | 4.0 |
Salmonella typhimurium/*immunology | 2 | 28.0 |
Endothelium, Vascular/cytology/immunology | 2 | 16.0 |
Immune Tolerance/*immunology | 6 | 12.0 |
Lymphocyte Activation/drug effects/*immunology | 2 | 4.0 |
Macrophages/cytology/drug effects/*immunology | 2 | 50.0 |
Mitogens | 2 | 2.0 |
Neutralization Tests | 2 | 0.0 |
T-Lymphocytes, Cytotoxic | 2 | 9.0 |
CD8-Positive T-Lymphocytes/*immunology | 6 | 1.0 |
Immunomagnetic Separation | 8 | 7.0 |
Enterotoxins/pharmacology | 4 | 6.0 |
Staphylococcus aureus/immunology | 2 | 1.0 |
Antibodies, Anti-Idiotypic/immunology | 2 | 5.0 |
Antigens, CD5/analysis | 2 | 4.0 |
Lymph Nodes/pathology | 2 | 0.0 |
Antigens, CD28/blood | 3 | 37.0 |
Antigens, Differentiation/blood | 2 | 18.0 |
Interleukin-10/blood | 2 | 2.0 |
Antigen-Presenting Cells/cytology/immunology | 3 | 37.0 |
Macrophages, Alveolar/immunology | 3 | 18.0 |
Transforming Growth Factor beta/secretion | 2 | 25.0 |
Membrane Glycoproteins/pharmacology | 6 | 10.0 |
Pinocytosis/immunology | 3 | 100.0 |
Skin/cytology/immunology | 2 | 11.0 |
Vaccines/*immunology | 2 | 28.0 |
Cell Survival/drug effects/immunology | 2 | 11.0 |
Interleukin-12/antagonists & inhibitors/secretion | 2 | 66.0 |
Apoptosis/drug effects/*immunology | 2 | 5.0 |
Caspases/antagonists & inhibitors | 2 | 4.0 |
Macrophages/cytology/immunology | 3 | 15.0 |
Monocytes/cytology/*immunology/metabolism | 3 | 25.0 |
T-Lymphocytes/*cytology/*immunology | 2 | 11.0 |
Tumor Necrosis Factor-alpha/immunology/*pharmacology | 2 | 10.0 |
Interferon-gamma, Recombinant/*pharmacology | 4 | 3.0 |
Microscopy, Immunoelectron | 6 | 1.0 |
Skin/*immunology | 4 | 3.0 |
Immune Tolerance/*physiology | 2 | 14.0 |
Necrosis | 4 | 1.0 |
Dimerization | 4 | 0.0 |
Langerhans Cells/cytology/immunology | 2 | 40.0 |
Measles virus/*immunology | 2 | 16.0 |
Genes, MHC Class I | 2 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/*metabolism | 2 | 1.0 |
Autoimmunity | 3 | 2.0 |
Macrophage-1 Antigen/metabolism | 2 | 2.0 |
Receptors, Interleukin-2/*metabolism | 2 | 2.0 |
Interleukin-12/metabolism/secretion | 2 | 50.0 |
Antigens, CD27/immunology | 2 | 22.0 |
Graft Rejection/*immunology/prevention & control | 2 | 28.0 |
*Antigens, CD34 | 3 | 4.0 |
Fetal Blood/cytology/*immunology | 3 | 15.0 |
Epitopes, T-Lymphocyte/immunology | 4 | 4.0 |
Myelin Basic Proteins/immunology | 2 | 2.0 |
CpG Islands/*immunology | 2 | 12.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Receptors, IgG/biosynthesis | 4 | 14.0 |
Cell Adhesion Molecules/analysis | 2 | 1.0 |
Fetal Blood/immunology | 4 | 5.0 |
Lymphocyte Function-Associated Antigen-1/analysis | 2 | 4.0 |
Antigens, CD/genetics/metabolism | 2 | 3.0 |
Antigens, CD80/genetics/metabolism | 3 | 60.0 |
Membrane Glycoproteins/genetics/metabolism | 2 | 2.0 |
Antibodies, Viral/biosynthesis | 2 | 5.0 |
Herpesvirus 4, Human/immunology | 3 | 4.0 |
Immunotherapy/*methods | 10 | 7.0 |
T-Lymphocyte Subsets | 2 | 1.0 |
Haptens/*pharmacology | 2 | 50.0 |
Macrophages/drug effects/immunology | 2 | 12.0 |
Nickel/pharmacology | 2 | 8.0 |
Picryl Chloride/pharmacology | 2 | 66.0 |
Histocompatibility Antigens Class II/*biosynthesis | 2 | 7.0 |
Human T-lymphotropic virus 1/*physiology | 2 | 7.0 |
T-Lymphocytes, Cytotoxic/drug effects/*immunology | 3 | 14.0 |
Umbilical Veins | 3 | 0.0 |
Antigens, CD/*genetics/immunology | 2 | 11.0 |
Antigens, CD80/genetics | 3 | 30.0 |
Membrane Glycoproteins/*genetics/immunology | 2 | 10.0 |
Antigens, Differentiation/*immunology/metabolism | 2 | 40.0 |
Urticaria/drug therapy | 2 | 66.0 |
Biosensing Techniques/*methods | 2 | 18.0 |
Colorimetry | 2 | 3.0 |
Gold/*chemistry | 2 | 40.0 |
Nanostructures | 2 | 40.0 |
Nucleic Acid Hybridization/*methods | 2 | 4.0 |
Point Mutation | 3 | 0.0 |
Sequence Analysis, DNA/*methods | 2 | 3.0 |
Lymphocyte Activation/genetics/immunology | 2 | 15.0 |
Antigens, CD/*immunology/metabolism | 4 | 12.0 |
Macrophage Activation/*immunology | 2 | 6.0 |
Porphyromonas gingivalis/*immunology | 2 | 9.0 |
5'-Nucleotidase/*metabolism | 2 | 22.0 |
Adenosine Monophosphate/metabolism | 2 | 18.0 |
Dendritic Cells/*enzymology | 3 | 42.0 |
Fura-2 | 2 | 7.0 |
Receptors, Purinergic P2/genetics/*metabolism | 2 | 100.0 |
Antigens, CD40 | 2 | 3.0 |
Membrane Glycoproteins | 3 | 6.0 |
Th2 Cells | 2 | 13.0 |
HLA-DR Antigens | 3 | 0.0 |
Langerhans Cells/cytology | 2 | 40.0 |
Cell Count/radiation effects | 2 | 100.0 |
Dose-Response Relationship, Radiation | 2 | 0.0 |
*Ultraviolet Rays | 5 | 2.0 |
Dendritic Cells/cytology/*drug effects/*immunology | 3 | 50.0 |
Immunoglobulins/metabolism | 12 | 11.0 |
Monocytes/immunology/virology | 2 | 25.0 |
Chemokines/biosynthesis/secretion | 2 | 50.0 |
T-Lymphocytes/cytology/*immunology/metabolism | 2 | 9.0 |
Tumor Necrosis Factor-alpha/biosynthesis/secretion | 2 | 28.0 |
Leukocytes, Mononuclear/metabolism | 8 | 3.0 |
Dinitrochlorobenzene/*pharmacology | 2 | 100.0 |
*Transfection | 2 | 0.0 |
ADP-ribosyl Cyclase | 5 | 1.0 |
B-Lymphocytes/*immunology/metabolism | 3 | 6.0 |
Cell Cycle/immunology | 2 | 6.0 |
L Cells (Cell Line) | 7 | 3.0 |
Macrophages/cytology | 2 | 2.0 |
Antigens, T-Independent/immunology/metabolism | 2 | 100.0 |
Receptors, Cell Surface/*metabolism | 3 | 0.0 |
Macrophages/*physiology | 2 | 2.0 |
B-Lymphocytes/*drug effects/immunology | 5 | 17.0 |
Methylprednisolone/therapeutic use | 2 | 4.0 |
Monocytes/*drug effects/immunology | 3 | 7.0 |
Antibodies, Blocking/pharmacology | 4 | 4.0 |
Lymphocyte Activation/genetics/*immunology | 2 | 11.0 |
Mast-Cell Sarcoma | 3 | 30.0 |
Membrane Glycoproteins/biosynthesis/genetics/*immunology | 2 | 28.0 |
Transfection/immunology | 2 | 4.0 |
Interferon-alpha/*biosynthesis | 3 | 17.0 |
HL-60 Cells | 3 | 0.0 |
Antigens, CD/biosynthesis/*blood | 2 | 28.0 |
Colony-Forming Units Assay | 2 | 0.0 |
Growth Substances/*pharmacology | 2 | 0.0 |
Hematopoietic Stem Cells/*cytology/*physiology | 2 | 25.0 |
Conserved Sequence | 4 | 0.0 |
Exons | 2 | 0.0 |
Immunoglobulins, Fc/genetics | 2 | 12.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
CD4-Positive T-Lymphocytes/metabolism | 4 | 3.0 |
Gamma Rays | 3 | 1.0 |
Lymphocyte Activation/*genetics | 2 | 8.0 |
Retroviridae/genetics | 3 | 0.0 |
Peptide Fragments/immunology/metabolism | 2 | 4.0 |
Antigens, CD40/*biosynthesis | 3 | 23.0 |
Cell Adhesion Molecules/immunology | 3 | 4.0 |
Signal Transduction/*physiology | 4 | 0.0 |
Antigen-Antibody Complex/immunology | 2 | 3.0 |
Antigens/*immunology | 2 | 2.0 |
Umbilical Veins/cytology | 3 | 1.0 |
Graft Rejection/immunology | 5 | 7.0 |
RNA, Messenger/genetics | 9 | 0.0 |
Bronchoalveolar Lavage Fluid/chemistry/cytology | 2 | 5.0 |
Interferon Type II/physiology | 4 | 4.0 |
Histocompatibility Antigens Class I/*biosynthesis | 2 | 5.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
CD8-Positive T-Lymphocytes/metabolism | 3 | 3.0 |
Immunotherapy, Adoptive/methods | 3 | 25.0 |
Leukapheresis/methods | 2 | 12.0 |
Forecasting | 2 | 0.0 |
DNA Methylation | 2 | 0.0 |
Interleukin-12/*immunology | 3 | 20.0 |
Leukocytes, Mononuclear/physiology | 2 | 6.0 |
Monocytes/cytology/drug effects/immunology | 2 | 20.0 |
Antigens, CD/analysis/*immunology | 2 | 5.0 |
Interleukin-10/*biosynthesis | 3 | 4.0 |
HIV Infections/*immunology | 8 | 1.0 |
Membrane Glycoproteins/*biosynthesis/genetics | 4 | 6.0 |
Receptors, Interleukin-2/biosynthesis | 4 | 3.0 |
Antigens, CD/*biosynthesis/*physiology | 2 | 50.0 |
Antigens, CD80/*biosynthesis/*physiology | 2 | 100.0 |
Dust | 2 | 6.0 |
Epitopes | 3 | 0.0 |
Membrane Glycoproteins/*biosynthesis/*physiology | 2 | 66.0 |
Mites/*immunology | 2 | 4.0 |
Binding, Competitive | 2 | 0.0 |
Glycosylation | 2 | 0.0 |
Models, Molecular | 3 | 0.0 |
Peptides/*metabolism | 2 | 1.0 |
Dendritic Cells/*drug effects | 7 | 63.0 |
Interleukin-12/*secretion | 3 | 50.0 |
Reproducibility of Results | 3 | 0.0 |
Antigen-Presenting Cells/drug effects/immunology | 3 | 27.0 |
Down-Regulation/drug effects/immunology | 3 | 15.0 |
Histocompatibility Antigens Class I/genetics | 2 | 2.0 |
Poly I-C/*pharmacology | 2 | 18.0 |
Antibody Formation/immunology | 3 | 6.0 |
Membrane Glycoproteins/*immunology/metabolism | 2 | 12.0 |
Double-Blind Method | 5 | 0.0 |
Hepatitis B Surface Antigens/immunology | 2 | 8.0 |
Immunotherapy, Adoptive/*methods | 2 | 5.0 |
Antigens, CD28/*biosynthesis | 2 | 11.0 |
CD4-Positive T-Lymphocytes/cytology/metabolism | 2 | 20.0 |
Immunoglobulin G/blood | 2 | 0.0 |
Rats, Inbred Lew | 3 | 1.0 |
Antigens, CD58/metabolism | 2 | 12.0 |
Vascular Cell Adhesion Molecule-1/metabolism | 2 | 2.0 |
Dendritic Cells/cytology/*drug effects/*physiology | 2 | 100.0 |
Antigen-Presenting Cells/*physiology | 3 | 8.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 3 | 0.0 |
Cancer Vaccines/immunology | 2 | 10.0 |
Growth Inhibitors/pharmacology | 2 | 1.0 |
Dendritic Cells/cytology/*immunology/*metabolism | 3 | 27.0 |
Membrane Glycoproteins/*immunology/*metabolism | 2 | 33.0 |
Lupus Erythematosus, Systemic/*blood | 2 | 6.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 2 | 0.0 |
Fluorometry | 2 | 2.0 |
Tumor Markers, Biological/*analysis | 2 | 0.0 |
Luciferases/metabolism | 2 | 0.0 |
CD4-Positive T-Lymphocytes/immunology/metabolism | 3 | 4.0 |
Hepacivirus/*immunology | 2 | 6.0 |
Interleukin-12/*metabolism | 3 | 23.0 |
Monocytes | 4 | 4.0 |
Lymphocyte Activation/*drug effects/immunology | 3 | 13.0 |
Antigens, CD/*genetics/physiology | 2 | 25.0 |
Antigens, CD40/*physiology | 4 | 11.0 |
Recurrence | 4 | 0.0 |
Clone Cells/immunology | 2 | 1.0 |
Immunologic Memory/*immunology | 3 | 9.0 |
Binding Sites | 6 | 0.0 |
Intercellular Adhesion Molecule-1/immunology/metabolism | 2 | 22.0 |
Growth Inhibitors/*physiology | 2 | 5.0 |
Interleukin-10/antagonists & inhibitors/biosynthesis | 2 | 66.0 |
Epitope Mapping | 2 | 0.0 |
Recombinant Proteins/biosynthesis/immunology | 2 | 9.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 2 | 0.0 |
Enzyme Activation/immunology | 3 | 2.0 |
Mitogen-Activated Protein Kinase 1 | 2 | 1.0 |
*Mitogen-Activated Protein Kinases | 2 | 0.0 |
Sarcoidosis, Pulmonary/*immunology | 2 | 11.0 |
*Genetic Vectors | 5 | 1.0 |
Recombination, Genetic | 4 | 0.0 |
Graft vs Host Disease/immunology | 2 | 6.0 |
Antigen-Presenting Cells/*immunology/pathology | 2 | 100.0 |
Interleukin-2/metabolism | 3 | 2.0 |
Apoptosis/*immunology | 3 | 1.0 |
NF-kappa B/*antagonists & inhibitors | 2 | 4.0 |
Proto-Oncogene Proteins/analysis | 2 | 1.0 |
*Vaccination | 2 | 3.0 |
Immunotherapy, Active/*methods | 2 | 18.0 |
Transforming Growth Factor beta/*immunology | 2 | 25.0 |
CD40 Ligand/immunology/pharmacology | 2 | 66.0 |
Lipopolysaccharides/immunology/pharmacology | 5 | 23.0 |
Dendritic Cells/immunology/*pathology/*virology | 2 | 100.0 |
Antigens, CD3/*metabolism | 2 | 4.0 |
Interphase/*immunology | 2 | 22.0 |
Antigens, CD/*biosynthesis/immunology | 2 | 8.0 |
Antigens, CD80/*biosynthesis/immunology | 2 | 50.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
Lymphoma, Follicular/immunology/pathology | 2 | 66.0 |
Reactive Oxygen Species/*metabolism | 2 | 1.0 |
Tonsil/metabolism | 2 | 11.0 |
T-Lymphocyte Subsets/*immunology/metabolism | 3 | 6.0 |
T-Lymphocytes, Suppressor-Effector/*immunology/metabolism | 2 | 50.0 |
Culture Techniques | 2 | 0.0 |
Multiple Myeloma/*immunology/pathology | 2 | 11.0 |
Antibodies, Blocking/immunology | 2 | 11.0 |
Candida albicans/immunology | 3 | 6.0 |
Dermatitis, Atopic/*immunology | 2 | 4.0 |
Antigens, Differentiation/*physiology | 3 | 3.0 |
Antigen-Antibody Reactions | 2 | 0.0 |
Cerebrospinal Fluid/cytology/immunology | 2 | 20.0 |
Antigen-Presenting Cells/*immunology/metabolism | 2 | 25.0 |
Membrane Glycoproteins/*immunology/physiology | 2 | 40.0 |
Cancer Vaccines/therapeutic use | 2 | 16.0 |
Feasibility Studies | 5 | 2.0 |
*Hematopoietic Stem Cell Transplantation | 2 | 0.0 |
Monocytes/*cytology/*immunology | 2 | 50.0 |
Cell Adhesion/physiology | 2 | 0.0 |
Dendritic Cells/metabolism/*physiology | 2 | 50.0 |
T-Lymphocytes/cytology/*immunology | 5 | 3.0 |
Antigens, CD80/biosynthesis/immunology/*metabolism | 2 | 100.0 |
Immunity, Cellular/*drug effects/immunology | 3 | 60.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
HIV-1/*pathogenicity/physiology | 2 | 6.0 |
Antigens, CD45/physiology | 2 | 13.0 |
Cricetulus | 2 | 0.0 |
Enzyme Activation | 4 | 0.0 |
Receptors, Antigen, B-Cell/*physiology | 2 | 2.0 |
B-Lymphocytes/metabolism | 3 | 1.0 |
Hodgkin Disease/*immunology/pathology | 3 | 18.0 |
Cytoplasm/*immunology | 2 | 12.0 |
Cell Division/radiation effects | 2 | 4.0 |
Antibodies, Monoclonal/*immunology | 2 | 0.0 |
Histocompatibility Testing | 4 | 0.0 |
*Peptides | 3 | 4.0 |
*Linkage (Genetics) | 2 | 0.0 |
Immune Tolerance/drug effects/immunology | 2 | 18.0 |
Hypersensitivity/immunology | 2 | 5.0 |
Tumor Escape | 2 | 50.0 |
Antiviral Agents/pharmacology | 2 | 3.0 |
HIV Core Protein p24/immunology | 2 | 5.0 |
HIV Envelope Protein gp120/immunology | 2 | 2.0 |
T-Lymphocytes/*immunology/virology | 2 | 11.0 |
Antigens, CD18/analysis | 2 | 9.0 |
Interleukin-4/analysis | 2 | 5.0 |
Animals, Genetically Modified | 2 | 0.0 |
Rats, Inbred F344 | 2 | 0.0 |
Spondylarthropathies/*immunology | 2 | 66.0 |
Antigens, CD11c/analysis | 2 | 20.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 6 | 0.0 |
Immunity, Mucosal | 2 | 2.0 |
Interleukin-1/secretion | 2 | 4.0 |
Receptors, Immunologic/analysis | 2 | 2.0 |
Epitopes/*immunology | 2 | 0.0 |
Antigens, CD28/*analysis | 2 | 10.0 |
Multiple Myeloma/*pathology | 2 | 3.0 |
Predictive Value of Tests | 2 | 0.0 |
Cell Count/drug effects | 2 | 2.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Antigens, CD/immunology/*physiology | 3 | 9.0 |
Membrane Glycoproteins/immunology/*physiology | 3 | 17.0 |
Hematopoietic Stem Cells/*cytology | 3 | 1.0 |
Hela Cells | 5 | 0.0 |
Antigens, CD4/metabolism | 3 | 0.0 |
*Lymphocyte Activation/drug effects | 3 | 2.0 |
Signal Transduction/drug effects/immunology | 4 | 8.0 |
T-Lymphocytes/immunology/*metabolism | 2 | 2.0 |
Metabolic Clearance Rate | 2 | 0.0 |
Gene Expression/drug effects | 3 | 0.0 |
Irritants/*pharmacology | 2 | 40.0 |
Interleukin-6/biosynthesis/immunology | 2 | 25.0 |
Thymidine/metabolism | 2 | 0.0 |
Lymphoma, B-Cell/metabolism | 3 | 27.0 |
T-Lymphocytes/*metabolism/pathology | 2 | 15.0 |
Kidney Transplantation/*immunology | 2 | 0.0 |
Sequence Alignment | 5 | 0.0 |
Cell Differentiation/*physiology | 4 | 1.0 |
Mice, Inbred A | 2 | 3.0 |
Th1 Cells/cytology/immunology/*metabolism | 2 | 50.0 |
Th2 Cells/cytology/immunology/*metabolism | 2 | 66.0 |
Immunosuppressive Agents/metabolism | 2 | 28.0 |
Thymus Gland/immunology | 2 | 3.0 |
Antigens, CD80/biosynthesis/*physiology | 2 | 50.0 |
Histocompatibility Antigens Class II/*immunology | 2 | 1.0 |
Dendritic Cells/*cytology/immunology/metabolism | 3 | 37.0 |
Fibroblasts/cytology/immunology | 2 | 18.0 |
*Antigens, CD80 | 2 | 33.0 |
Drug Evaluation, Preclinical | 3 | 1.0 |
Immunoglobulin Class Switching | 2 | 10.0 |
*Immunologic Memory/drug effects | 2 | 40.0 |
Antigens, CD/biosynthesis/drug effects | 3 | 33.0 |
Macrophages/*cytology | 3 | 9.0 |
Membrane Glycoproteins/biosynthesis/drug effects | 2 | 50.0 |
Antigens, CD31/analysis | 2 | 2.0 |
Lymphocyte Subsets/*immunology | 2 | 1.0 |
Antigens, CD80/*biosynthesis/genetics | 2 | 22.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/physiology | 2 | 7.0 |
Membrane Glycoproteins/biosynthesis/*physiology | 2 | 13.0 |
Interleukin-4/genetics | 2 | 5.0 |
Receptors, Interleukin-2/immunology | 2 | 3.0 |
*Chromosome Mapping | 2 | 0.0 |
Exons/genetics | 2 | 0.0 |
Sequence Homology | 2 | 0.0 |
Leukemia, Myeloid, Chronic/*immunology/therapy | 2 | 66.0 |
Antigens, Differentiation/chemistry/*metabolism | 2 | 22.0 |
Antibodies, Monoclonal/diagnostic use | 3 | 0.0 |
Recombinant Fusion Proteins/*immunology | 2 | 9.0 |
Receptors, Tumor Necrosis Factor/physiology | 2 | 2.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
Neutrophils/immunology | 2 | 1.0 |
Antigens, CD/chemistry/genetics/*metabolism | 2 | 6.0 |
Antigens, CD80/chemistry/genetics/*metabolism | 2 | 100.0 |
Membrane Glycoproteins/chemistry/genetics/*metabolism | 2 | 8.0 |
Lymphoma/*immunology | 2 | 6.0 |
Cytotoxicity, Immunologic/drug effects | 2 | 1.0 |
Clonal Anergy/drug effects | 2 | 50.0 |
Antigens, Neoplasm/analysis | 3 | 0.0 |
*Membrane Glycoproteins | 3 | 0.0 |
Macrophages/*metabolism | 2 | 0.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Bone Marrow Cells | 2 | 0.0 |
Antigens, CD28/*immunology/metabolism | 3 | 42.0 |
Clonal Anergy | 6 | 16.0 |
T-Lymphocytes | 2 | 0.0 |
Solutions | 2 | 1.0 |
Antigens, CD/analysis/*biosynthesis | 2 | 7.0 |
Antibody Formation | 6 | 1.0 |
Tonsil/cytology | 5 | 5.0 |
Microscopy, Phase-Contrast | 2 | 2.0 |
Autoantigens/*immunology | 2 | 1.0 |
Epidermis/immunology | 2 | 9.0 |
Antigens, Differentiation/physiology | 6 | 11.0 |
Antibodies | 2 | 0.0 |
Adjuvants, Immunologic/*therapeutic use | 2 | 2.0 |
Interferon-beta/*therapeutic use | 3 | 13.0 |
Immunosuppression | 4 | 2.0 |
Dendritic Cells/classification/*immunology | 2 | 28.0 |
Antigens, CD28/*pharmacology | 2 | 33.0 |
Membrane Glycoproteins/*pharmacology | 3 | 3.0 |
Interleukin-2/immunology | 2 | 1.0 |
Ovalbumin/immunology | 4 | 8.0 |
Mycobacterium bovis/*immunology | 2 | 10.0 |
Tumor Necrosis Factor-alpha/*metabolism | 2 | 0.0 |
Breast Neoplasms/immunology/therapy | 2 | 33.0 |
HLA Antigens/metabolism | 2 | 6.0 |
Receptors, Interleukin-4 | 2 | 2.0 |
Histocompatibility Antigens Class II | 2 | 4.0 |
Antigens, CD/analysis/biosynthesis/genetics | 2 | 66.0 |
*Models, Immunological | 2 | 4.0 |
Neoplasm Proteins/genetics/*immunology | 2 | 14.0 |
Autoimmunity/*physiology | 2 | 15.0 |
Interleukin-5/secretion | 2 | 25.0 |
Cattle/*immunology | 2 | 11.0 |
HIV-1/*genetics | 3 | 0.0 |
Antigens, CD27/biosynthesis | 2 | 33.0 |
Lymphocyte Depletion | 2 | 1.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*physiology | 2 | 11.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
S100 Proteins/metabolism | 2 | 1.0 |
*Immunity, Cellular | 2 | 1.0 |
Antigens, CD28/chemistry/*metabolism | 3 | 60.0 |
Binding, Competitive/immunology | 3 | 3.0 |
Interleukin-2/secretion | 3 | 4.0 |
Receptors, Immunologic/biosynthesis | 2 | 6.0 |
Dinoprostone/pharmacology | 3 | 3.0 |
*Gene Expression Regulation | 3 | 0.0 |
Cell Survival/immunology | 2 | 3.0 |
*Lymphocyte Cooperation | 2 | 7.0 |
Immunoglobulins/immunology | 2 | 4.0 |
Immune System/*physiology | 2 | 3.0 |
Clonal Anergy/immunology | 2 | 14.0 |
Immunoglobulins/*immunology | 2 | 7.0 |
Receptors, Antigen, T-Cell/*immunology | 2 | 1.0 |
Skin/immunology | 2 | 2.0 |
Neoplasms/therapy | 2 | 4.0 |
Leukemia, Myeloid/*immunology | 3 | 7.0 |
Quinazolines/pharmacology | 2 | 2.0 |
Dendritic Cells/cytology/immunology/metabolism | 2 | 66.0 |
Membrane Glycoproteins/analysis/metabolism | 2 | 15.0 |
Flavonoids/pharmacology | 4 | 1.0 |
Drugs, Chinese Herbal/*pharmacology | 2 | 4.0 |
Antigens, Bacterial/*immunology | 2 | 1.0 |
Mycobacterium leprae/*immunology | 2 | 6.0 |
Cohort Studies | 2 | 0.0 |
Linear Models | 2 | 0.0 |
Probability | 4 | 0.0 |
Interleukins/pharmacology | 2 | 2.0 |
Lectins, C-Type/metabolism | 2 | 13.0 |
Receptors, Interleukin-2/analysis | 2 | 0.0 |
Dendritic Cells/*chemistry | 2 | 22.0 |
Granulocyte Colony-Stimulating Factor/*therapeutic use | 2 | 3.0 |
Cytokines/immunology/metabolism | 3 | 13.0 |
CD40 Ligand/metabolism | 2 | 8.0 |
Membrane Glycoproteins/antagonists & inhibitors/immunology | 2 | 66.0 |
Bone Marrow Cells/cytology/drug effects/immunology | 2 | 28.0 |
Chemokines/biosynthesis | 4 | 10.0 |
Oligodeoxyribonucleotides/pharmacology | 2 | 8.0 |
Lipopolysaccharides/immunology/*pharmacology | 2 | 50.0 |
Sampling Studies | 2 | 1.0 |
Protein Subunits/biosynthesis | 2 | 15.0 |
Antineoplastic Agents/pharmacology | 3 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Immunoglobulin M/immunology | 2 | 1.0 |
*Liver Transplantation | 2 | 1.0 |
Macrophages/drug effects/*immunology | 2 | 10.0 |
Dendritic Cells/drug effects/immunology/*metabolism | 2 | 40.0 |
Hematopoietic Stem Cells/cytology/metabolism | 2 | 8.0 |
Macrophage Activation/immunology | 2 | 5.0 |
*Down-Regulation | 2 | 0.0 |
Follow-Up Studies | 4 | 0.0 |
Desensitization, Immunologic | 2 | 14.0 |
Antiretroviral Therapy, Highly Active | 2 | 0.0 |
Longitudinal Studies | 2 | 0.0 |
Interferon Alfa-2b/*pharmacology | 2 | 9.0 |
Antigens, Viral/*immunology | 2 | 2.0 |
Myeloid Cells/*immunology | 2 | 20.0 |
Adjuvants, Immunologic/therapeutic use | 2 | 4.0 |
Herpesvirus 1, Human/immunology | 2 | 28.0 |
Models, Immunological | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Dependovirus/*genetics | 2 | 2.0 |
HLA-DR Antigens/biosynthesis/immunology | 3 | 60.0 |
Sirolimus/*pharmacology | 2 | 6.0 |
Skin/cytology/*immunology | 2 | 20.0 |
Organ Specificity | 2 | 0.0 |
Diabetes Mellitus, Type 1/*immunology | 3 | 4.0 |
Diabetes Mellitus, Type 2/immunology | 2 | 50.0 |
Interferon Type I, Recombinant/pharmacology | 2 | 6.0 |
Interleukin-12/blood | 2 | 9.0 |
T-Lymphocyte Subsets/*immunology/secretion | 3 | 25.0 |
Indicators and Reagents | 2 | 0.0 |
I-kappa B/metabolism | 4 | 5.0 |
*Viral Proteins | 2 | 1.0 |
*Cell Adhesion Molecules | 2 | 0.0 |
*Protein-Serine-Threonine Kinases | 2 | 0.0 |
Vaccination | 2 | 1.0 |
Interferon-alpha/secretion | 2 | 50.0 |
Dendritic Cells/cytology/*drug effects/metabolism | 2 | 100.0 |
